US20090286962A1 - Chimeric antibodies with part new world primate binding regions - Google Patents
Chimeric antibodies with part new world primate binding regions Download PDFInfo
- Publication number
- US20090286962A1 US20090286962A1 US12/158,034 US15803406A US2009286962A1 US 20090286962 A1 US20090286962 A1 US 20090286962A1 US 15803406 A US15803406 A US 15803406A US 2009286962 A1 US2009286962 A1 US 2009286962A1
- Authority
- US
- United States
- Prior art keywords
- cdr
- human
- new world
- antibody
- sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 230000027455 binding Effects 0.000 title claims abstract description 71
- 241000288906 Primates Species 0.000 title claims abstract description 61
- 108091007433 antigens Proteins 0.000 claims abstract description 77
- 102000036639 antigens Human genes 0.000 claims abstract description 77
- 239000000427 antigen Substances 0.000 claims abstract description 76
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 55
- 229920001184 polypeptide Polymers 0.000 claims abstract description 52
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 52
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims description 44
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims description 44
- 108090000623 proteins and genes Proteins 0.000 claims description 44
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 claims description 39
- 101000611183 Homo sapiens Tumor necrosis factor Proteins 0.000 claims description 27
- 238000000034 method Methods 0.000 claims description 26
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 22
- 210000004602 germ cell Anatomy 0.000 claims description 19
- 241001515942 marmosets Species 0.000 claims description 17
- 102000057041 human TNF Human genes 0.000 claims description 12
- 241000288943 Callitrichinae Species 0.000 claims description 8
- 150000001413 amino acids Chemical class 0.000 claims description 8
- 108091034117 Oligonucleotide Proteins 0.000 claims description 6
- 238000000137 annealing Methods 0.000 claims description 5
- 230000029087 digestion Effects 0.000 claims description 4
- 239000002253 acid Substances 0.000 claims description 3
- 102100035360 Cerebellar degeneration-related antigen 1 Human genes 0.000 claims 25
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 54
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 18
- 102000004169 proteins and genes Human genes 0.000 description 18
- 210000004027 cell Anatomy 0.000 description 16
- 241000282709 Aotus trivirgatus Species 0.000 description 15
- 241000282412 Homo Species 0.000 description 15
- 102100040247 Tumor necrosis factor Human genes 0.000 description 15
- 108060003951 Immunoglobulin Proteins 0.000 description 14
- 150000001875 compounds Chemical class 0.000 description 14
- 239000012634 fragment Substances 0.000 description 14
- 102000018358 immunoglobulin Human genes 0.000 description 14
- 230000000295 complement effect Effects 0.000 description 11
- 239000000203 mixture Substances 0.000 description 11
- 102000005962 receptors Human genes 0.000 description 11
- 108020003175 receptors Proteins 0.000 description 11
- 241000699666 Mus <mouse, genus> Species 0.000 description 10
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 10
- 208000035475 disorder Diseases 0.000 description 10
- 206010039073 rheumatoid arthritis Diseases 0.000 description 10
- 238000013459 approach Methods 0.000 description 9
- 102000004127 Cytokines Human genes 0.000 description 8
- 108090000695 Cytokines Proteins 0.000 description 8
- 108020004414 DNA Proteins 0.000 description 8
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 8
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 8
- 201000010099 disease Diseases 0.000 description 8
- 230000001225 therapeutic effect Effects 0.000 description 8
- 102100035361 Cerebellar degeneration-related protein 2 Human genes 0.000 description 7
- 101000737796 Homo sapiens Cerebellar degeneration-related protein 2 Proteins 0.000 description 7
- 206010061218 Inflammation Diseases 0.000 description 7
- 230000001976 improved effect Effects 0.000 description 7
- 230000004054 inflammatory process Effects 0.000 description 7
- 239000002773 nucleotide Substances 0.000 description 7
- 125000003729 nucleotide group Chemical group 0.000 description 7
- 241000894007 species Species 0.000 description 7
- 238000010367 cloning Methods 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 230000002757 inflammatory effect Effects 0.000 description 6
- 238000002560 therapeutic procedure Methods 0.000 description 6
- 208000011231 Crohn disease Diseases 0.000 description 5
- 102100033732 Tumor necrosis factor receptor superfamily member 1A Human genes 0.000 description 5
- 101710187830 Tumor necrosis factor receptor superfamily member 1B Proteins 0.000 description 5
- 102100033733 Tumor necrosis factor receptor superfamily member 1B Human genes 0.000 description 5
- 230000004913 activation Effects 0.000 description 5
- 230000007423 decrease Effects 0.000 description 5
- 239000003937 drug carrier Substances 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 229960000598 infliximab Drugs 0.000 description 5
- 230000001404 mediated effect Effects 0.000 description 5
- 230000004048 modification Effects 0.000 description 5
- 238000012986 modification Methods 0.000 description 5
- 230000035772 mutation Effects 0.000 description 5
- 210000000440 neutrophil Anatomy 0.000 description 5
- 230000000770 proinflammatory effect Effects 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 description 4
- 241000288950 Callithrix jacchus Species 0.000 description 4
- 241000282836 Camelus dromedarius Species 0.000 description 4
- 241000282513 Cebidae Species 0.000 description 4
- 108700005091 Immunoglobulin Genes Proteins 0.000 description 4
- 206010040070 Septic Shock Diseases 0.000 description 4
- 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 description 4
- 238000002835 absorbance Methods 0.000 description 4
- 231100000135 cytotoxicity Toxicity 0.000 description 4
- 230000003013 cytotoxicity Effects 0.000 description 4
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 4
- 210000002950 fibroblast Anatomy 0.000 description 4
- 210000004408 hybridoma Anatomy 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 210000002540 macrophage Anatomy 0.000 description 4
- 239000008194 pharmaceutical composition Substances 0.000 description 4
- 239000002953 phosphate buffered saline Substances 0.000 description 4
- 230000035755 proliferation Effects 0.000 description 4
- 238000001525 receptor binding assay Methods 0.000 description 4
- 102000003298 tumor necrosis factor receptor Human genes 0.000 description 4
- 241001062548 Alouatta guariba Species 0.000 description 3
- 241000282672 Ateles sp. Species 0.000 description 3
- 241000282688 Callicebus Species 0.000 description 3
- 102000011727 Caspases Human genes 0.000 description 3
- 108010076667 Caspases Proteins 0.000 description 3
- 238000002965 ELISA Methods 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 3
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 3
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 3
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 3
- 108010002352 Interleukin-1 Proteins 0.000 description 3
- 102000000589 Interleukin-1 Human genes 0.000 description 3
- 108090001005 Interleukin-6 Proteins 0.000 description 3
- 108090001007 Interleukin-8 Proteins 0.000 description 3
- 241000282675 Lagothrix Species 0.000 description 3
- 241000282577 Pan troglodytes Species 0.000 description 3
- 241000282695 Saimiri Species 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 230000006907 apoptotic process Effects 0.000 description 3
- 206010003246 arthritis Diseases 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 238000002784 cytotoxicity assay Methods 0.000 description 3
- 231100000263 cytotoxicity test Toxicity 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 230000001900 immune effect Effects 0.000 description 3
- 230000028993 immune response Effects 0.000 description 3
- 230000002163 immunogen Effects 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 208000027866 inflammatory disease Diseases 0.000 description 3
- 239000003446 ligand Substances 0.000 description 3
- 210000004698 lymphocyte Anatomy 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 229910021645 metal ion Inorganic materials 0.000 description 3
- 238000006386 neutralization reaction Methods 0.000 description 3
- 230000007170 pathology Effects 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 108020003519 protein disulfide isomerase Proteins 0.000 description 3
- 238000005215 recombination Methods 0.000 description 3
- 230000006798 recombination Effects 0.000 description 3
- 230000002441 reversible effect Effects 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 210000005222 synovial tissue Anatomy 0.000 description 3
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 description 2
- 241001502973 Aotus nancymaae Species 0.000 description 2
- 208000023275 Autoimmune disease Diseases 0.000 description 2
- 102100027955 BAG family molecular chaperone regulator 4 Human genes 0.000 description 2
- 101710089799 BAG family molecular chaperone regulator 4 Proteins 0.000 description 2
- 241000282693 Cercopithecidae Species 0.000 description 2
- 206010009900 Colitis ulcerative Diseases 0.000 description 2
- 208000009386 Experimental Arthritis Diseases 0.000 description 2
- 108091006020 Fc-tagged proteins Proteins 0.000 description 2
- 208000009329 Graft vs Host Disease Diseases 0.000 description 2
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 2
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 2
- 102000006496 Immunoglobulin Heavy Chains Human genes 0.000 description 2
- 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 description 2
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 2
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 2
- 241000282560 Macaca mulatta Species 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 102000016943 Muramidase Human genes 0.000 description 2
- 108010014251 Muramidase Proteins 0.000 description 2
- 241001529936 Murinae Species 0.000 description 2
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 2
- 241000282579 Pan Species 0.000 description 2
- 108010038036 Receptor Activator of Nuclear Factor-kappa B Proteins 0.000 description 2
- 102000010498 Receptor Activator of Nuclear Factor-kappa B Human genes 0.000 description 2
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 description 2
- 241000219061 Rheum Species 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- 206010044248 Toxic shock syndrome Diseases 0.000 description 2
- 231100000650 Toxic shock syndrome Toxicity 0.000 description 2
- 201000006704 Ulcerative Colitis Diseases 0.000 description 2
- 102000009524 Vascular Endothelial Growth Factor A Human genes 0.000 description 2
- RJURFGZVJUQBHK-UHFFFAOYSA-N actinomycin D Natural products CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)NC4C(=O)NC(C(N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-UHFFFAOYSA-N 0.000 description 2
- 201000000028 adult respiratory distress syndrome Diseases 0.000 description 2
- 230000009824 affinity maturation Effects 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000002917 arthritic effect Effects 0.000 description 2
- -1 c-IAP Proteins 0.000 description 2
- 210000000845 cartilage Anatomy 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 230000001472 cytotoxic effect Effects 0.000 description 2
- 230000008034 disappearance Effects 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000013604 expression vector Substances 0.000 description 2
- 102000054766 genetic haplotypes Human genes 0.000 description 2
- 208000024908 graft versus host disease Diseases 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 238000003018 immunoassay Methods 0.000 description 2
- 230000002998 immunogenetic effect Effects 0.000 description 2
- 230000005847 immunogenicity Effects 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 230000028709 inflammatory response Effects 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 239000007951 isotonicity adjuster Substances 0.000 description 2
- 210000001503 joint Anatomy 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 229960000274 lysozyme Drugs 0.000 description 2
- 239000004325 lysozyme Substances 0.000 description 2
- 235000010335 lysozyme Nutrition 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 210000001616 monocyte Anatomy 0.000 description 2
- 229940126619 mouse monoclonal antibody Drugs 0.000 description 2
- 210000004400 mucous membrane Anatomy 0.000 description 2
- 201000006417 multiple sclerosis Diseases 0.000 description 2
- 238000002703 mutagenesis Methods 0.000 description 2
- 231100000350 mutagenesis Toxicity 0.000 description 2
- 210000002997 osteoclast Anatomy 0.000 description 2
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 2
- 238000002823 phage display Methods 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 230000002685 pulmonary effect Effects 0.000 description 2
- 238000003127 radioimmunoassay Methods 0.000 description 2
- 230000008707 rearrangement Effects 0.000 description 2
- 238000010188 recombinant method Methods 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 210000003556 vascular endothelial cell Anatomy 0.000 description 2
- 239000013598 vector Substances 0.000 description 2
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- HVAUUPRFYPCOCA-AREMUKBSSA-N 2-O-acetyl-1-O-hexadecyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCOC[C@@H](OC(C)=O)COP([O-])(=O)OCC[N+](C)(C)C HVAUUPRFYPCOCA-AREMUKBSSA-N 0.000 description 1
- PAYROHWFGZADBR-UHFFFAOYSA-N 2-[[4-amino-5-(5-iodo-4-methoxy-2-propan-2-ylphenoxy)pyrimidin-2-yl]amino]propane-1,3-diol Chemical compound C1=C(I)C(OC)=CC(C(C)C)=C1OC1=CN=C(NC(CO)CO)N=C1N PAYROHWFGZADBR-UHFFFAOYSA-N 0.000 description 1
- UAIUNKRWKOVEES-UHFFFAOYSA-N 3,3',5,5'-tetramethylbenzidine Chemical compound CC1=C(N)C(C)=CC(C=2C=C(C)C(N)=C(C)C=2)=C1 UAIUNKRWKOVEES-UHFFFAOYSA-N 0.000 description 1
- QCVGEOXPDFCNHA-UHFFFAOYSA-N 5,5-dimethyl-2,4-dioxo-1,3-oxazolidine-3-carboxamide Chemical compound CC1(C)OC(=O)N(C(N)=O)C1=O QCVGEOXPDFCNHA-UHFFFAOYSA-N 0.000 description 1
- 102000011767 Acute-Phase Proteins Human genes 0.000 description 1
- 108010062271 Acute-Phase Proteins Proteins 0.000 description 1
- 206010002556 Ankylosing Spondylitis Diseases 0.000 description 1
- 208000006386 Bone Resorption Diseases 0.000 description 1
- 208000020084 Bone disease Diseases 0.000 description 1
- 102100027207 CD27 antigen Human genes 0.000 description 1
- 101150013553 CD40 gene Proteins 0.000 description 1
- 206010006895 Cachexia Diseases 0.000 description 1
- 208000020446 Cardiac disease Diseases 0.000 description 1
- 102000003952 Caspase 3 Human genes 0.000 description 1
- 108090000397 Caspase 3 Proteins 0.000 description 1
- 102000000844 Cell Surface Receptors Human genes 0.000 description 1
- 108010001857 Cell Surface Receptors Proteins 0.000 description 1
- 235000008733 Citrus aurantifolia Nutrition 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 102000029816 Collagenase Human genes 0.000 description 1
- 108060005980 Collagenase Proteins 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 108091035707 Consensus sequence Proteins 0.000 description 1
- 241000699802 Cricetulus griseus Species 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 108010092160 Dactinomycin Proteins 0.000 description 1
- 102100038713 Death domain-containing protein CRADD Human genes 0.000 description 1
- 241000238557 Decapoda Species 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 206010014824 Endotoxic shock Diseases 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 108010008165 Etanercept Proteins 0.000 description 1
- 101150064015 FAS gene Proteins 0.000 description 1
- 102100026693 FAS-associated death domain protein Human genes 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 241000282575 Gorilla Species 0.000 description 1
- 201000005569 Gout Diseases 0.000 description 1
- 206010018634 Gouty Arthritis Diseases 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 101000690301 Homo sapiens Aldo-keto reductase family 1 member C4 Proteins 0.000 description 1
- 101000914511 Homo sapiens CD27 antigen Proteins 0.000 description 1
- 101000957914 Homo sapiens Death domain-containing protein CRADD Proteins 0.000 description 1
- 101001057612 Homo sapiens Dual specificity protein phosphatase 5 Proteins 0.000 description 1
- 101000911074 Homo sapiens FAS-associated death domain protein Proteins 0.000 description 1
- 101000946889 Homo sapiens Monocyte differentiation antigen CD14 Proteins 0.000 description 1
- 101001116548 Homo sapiens Protein CBFA2T1 Proteins 0.000 description 1
- 101001109145 Homo sapiens Receptor-interacting serine/threonine-protein kinase 1 Proteins 0.000 description 1
- 101000851376 Homo sapiens Tumor necrosis factor receptor superfamily member 8 Proteins 0.000 description 1
- 101000850748 Homo sapiens Tumor necrosis factor receptor type 1-associated DEATH domain protein Proteins 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 102000004889 Interleukin-6 Human genes 0.000 description 1
- 102000004890 Interleukin-8 Human genes 0.000 description 1
- 206010023203 Joint destruction Diseases 0.000 description 1
- 206010023330 Keloid scar Diseases 0.000 description 1
- 208000019693 Lung disease Diseases 0.000 description 1
- 102000008072 Lymphokines Human genes 0.000 description 1
- 108010074338 Lymphokines Proteins 0.000 description 1
- 102000004083 Lymphotoxin-alpha Human genes 0.000 description 1
- 108090000542 Lymphotoxin-alpha Proteins 0.000 description 1
- 102000003959 Lymphotoxin-beta Human genes 0.000 description 1
- 108090000362 Lymphotoxin-beta Proteins 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 102000005741 Metalloproteases Human genes 0.000 description 1
- 108010006035 Metalloproteases Proteins 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 102100035877 Monocyte differentiation antigen CD14 Human genes 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 241000238367 Mya arenaria Species 0.000 description 1
- 208000000112 Myalgia Diseases 0.000 description 1
- 108091008604 NGF receptors Proteins 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010029164 Nephrotic syndrome Diseases 0.000 description 1
- UIURLCFDWDKKBF-HYXAFXHYSA-N O=N/C=N\C1=CC1 Chemical compound O=N/C=N\C1=CC1 UIURLCFDWDKKBF-HYXAFXHYSA-N 0.000 description 1
- 108091008606 PDGF receptors Proteins 0.000 description 1
- 241000282520 Papio Species 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 108010003541 Platelet Activating Factor Proteins 0.000 description 1
- 102000011653 Platelet-Derived Growth Factor Receptors Human genes 0.000 description 1
- 229920002732 Polyanhydride Polymers 0.000 description 1
- 229920000954 Polyglycolide Polymers 0.000 description 1
- 229920001710 Polyorthoester Polymers 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 241000282405 Pongo abelii Species 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 108010025832 RANK Ligand Proteins 0.000 description 1
- 102100022501 Receptor-interacting serine/threonine-protein kinase 1 Human genes 0.000 description 1
- 206010063837 Reperfusion injury Diseases 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 241000288961 Saguinus imperator Species 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 206010053879 Sepsis syndrome Diseases 0.000 description 1
- 201000010001 Silicosis Diseases 0.000 description 1
- 108010003723 Single-Domain Antibodies Proteins 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- 206010051379 Systemic Inflammatory Response Syndrome Diseases 0.000 description 1
- 108091008874 T cell receptors Proteins 0.000 description 1
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 1
- 108090000925 TNF receptor-associated factor 2 Proteins 0.000 description 1
- 101150056647 TNFRSF4 gene Proteins 0.000 description 1
- 102100034779 TRAF family member-associated NF-kappa-B activator Human genes 0.000 description 1
- 108010006785 Taq Polymerase Proteins 0.000 description 1
- 235000011941 Tilia x europaea Nutrition 0.000 description 1
- 102100024568 Tumor necrosis factor ligand superfamily member 11 Human genes 0.000 description 1
- 102100033725 Tumor necrosis factor receptor superfamily member 16 Human genes 0.000 description 1
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 description 1
- 102100036857 Tumor necrosis factor receptor superfamily member 8 Human genes 0.000 description 1
- 102100033081 Tumor necrosis factor receptor type 1-associated DEATH domain protein Human genes 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 239000003070 absorption delaying agent Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 229960002964 adalimumab Drugs 0.000 description 1
- 208000011341 adult acute respiratory distress syndrome Diseases 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 230000001668 ameliorated effect Effects 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 230000002491 angiogenic effect Effects 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 230000009831 antigen interaction Effects 0.000 description 1
- 230000005775 apoptotic pathway Effects 0.000 description 1
- 201000004982 autoimmune uveitis Diseases 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 239000013060 biological fluid Substances 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 239000012472 biological sample Substances 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 230000024279 bone resorption Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- DQXBYHZEEUGOBF-UHFFFAOYSA-N but-3-enoic acid;ethene Chemical compound C=C.OC(=O)CC=C DQXBYHZEEUGOBF-UHFFFAOYSA-N 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 230000021164 cell adhesion Effects 0.000 description 1
- 238000001516 cell proliferation assay Methods 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000008614 cellular interaction Effects 0.000 description 1
- 239000013043 chemical agent Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 210000001612 chondrocyte Anatomy 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 229960002424 collagenase Drugs 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- ALEXXDVDDISNDU-JZYPGELDSA-N cortisol 21-acetate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)C)(O)[C@@]1(C)C[C@@H]2O ALEXXDVDDISNDU-JZYPGELDSA-N 0.000 description 1
- 229960000640 dactinomycin Drugs 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 239000002612 dispersion medium Substances 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 125000002228 disulfide group Chemical group 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 235000014103 egg white Nutrition 0.000 description 1
- 210000000969 egg white Anatomy 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 238000012407 engineering method Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 229960000403 etanercept Drugs 0.000 description 1
- 239000005038 ethylene vinyl acetate Substances 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 108010052621 fas Receptor Proteins 0.000 description 1
- 102000018823 fas Receptor Human genes 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 239000000833 heterodimer Substances 0.000 description 1
- 102000043381 human DUSP5 Human genes 0.000 description 1
- 102000054751 human RUNX1T1 Human genes 0.000 description 1
- 230000005661 hydrophobic surface Effects 0.000 description 1
- 239000012642 immune effector Substances 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000000984 immunochemical effect Effects 0.000 description 1
- 238000003364 immunohistochemistry Methods 0.000 description 1
- 229940121354 immunomodulator Drugs 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 230000004968 inflammatory condition Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 229940102223 injectable solution Drugs 0.000 description 1
- 229940047124 interferons Drugs 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 230000031146 intracellular signal transduction Effects 0.000 description 1
- 230000004068 intracellular signaling Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 208000018937 joint inflammation Diseases 0.000 description 1
- 208000011379 keloid formation Diseases 0.000 description 1
- 210000002510 keratinocyte Anatomy 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 239000004571 lime Substances 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000008297 liquid dosage form Substances 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 239000004530 micro-emulsion Substances 0.000 description 1
- ZAHQPTJLOCWVPG-UHFFFAOYSA-N mitoxantrone dihydrochloride Chemical compound Cl.Cl.O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO ZAHQPTJLOCWVPG-UHFFFAOYSA-N 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 231100000219 mutagenic Toxicity 0.000 description 1
- 230000003505 mutagenic effect Effects 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 230000007310 pathophysiology Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 210000004976 peripheral blood cell Anatomy 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 description 1
- 229920000747 poly(lactic acid) Polymers 0.000 description 1
- 239000004633 polyglycolic acid Substances 0.000 description 1
- 239000004626 polylactic acid Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 230000034190 positive regulation of NF-kappaB transcription factor activity Effects 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002947 procoagulating effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 208000005069 pulmonary fibrosis Diseases 0.000 description 1
- 201000003651 pulmonary sarcoidosis Diseases 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- 239000008299 semisolid dosage form Substances 0.000 description 1
- 230000036303 septic shock Effects 0.000 description 1
- 238000002864 sequence alignment Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 230000007781 signaling event Effects 0.000 description 1
- 239000007909 solid dosage form Substances 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 210000004988 splenocyte Anatomy 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000004654 survival pathway Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 210000001258 synovial membrane Anatomy 0.000 description 1
- 210000002437 synoviocyte Anatomy 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000009772 tissue formation Effects 0.000 description 1
- 208000037816 tissue injury Diseases 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 230000006433 tumor necrosis factor production Effects 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 230000008728 vascular permeability Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/241—Tumor Necrosis Factors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
Definitions
- the present invention relates to engineered antibody polypeptides. More particularly, the present invention provides antibody polypeptides comprising an antigen binding site, wherein the antigen binding site comprises a human variable domain having at least one New World Primate CDR. In particular the present invention relates to antibody polypeptides directed against TNF- ⁇ .
- TNF- ⁇ Tumor Necrosis Factor- ⁇
- RA rheumatoid arthritis
- Crohn's disease Crohn's disease
- ulcerative colitis and other bowel disorders
- psoriasis toxic shock
- graft versus host disease and multiple sclerosis.
- the pro-inflammatory actions of TNF- ⁇ result in tissue injury, such as inducing procoagulant activity on vascular endothelial cells (Pober, et al., 1986, J.
- TNF- ⁇ is synthesized as a 26 kD transmembrane precursor protein with an intracellular tail that is cleaved by a TNF- ⁇ -converting metalloproteinase enzyme and then secreted as a 17 kD soluble protein.
- the active form consists of a homotrimer of the 17 kD monomers which interacts with two different cell surface receptors, p55 TNFR1 and p75 TNFR2.
- p55 TNFR1 and p75 TNFR2 cell surface receptors
- p75 receptor is implicated in triggering lymphocyte proliferation
- the p55 receptor is implicated in TNF-mediated cytotoxicity, apoptosis, antiviral activity, fibroblast proliferation and NT- ⁇ B activation (see Locksley et al., 2001, Cell 104: 487-501).
- the TNF receptors are members of a family of membrane proteins including the NGF receptor, Fas antigen, CD27, CD30, CD40, Ox40 and the receptor for the lymphotoxin ⁇ / ⁇ heterodimer. Binding of receptor by the homotrimer induces aggregation of receptors into small clusters of two or three molecules of either p55 or p75.
- TNF- ⁇ is produced primarily by activated macrophages and T lymphocytes, but also by neutrophils, endothelial cells, keratinocytes and fibroblasts during acute inflammatory reactions. TNF- ⁇ is at the apex of the cascade of pro-inflammatory cytokines (Reviewed in Feldmann & Maini, 2001, Ann. Rev. Immunol.
- This cytokine induces the expression or release of additional proinflammatory cytokines, particularly IL-1 und IL-6 (see, for example, Rutgeerts et al., 2004, Gastroenterology 126: 1593-1610). Inhibition of TNF- ⁇ inhibits the production of inflammatory cytokines including IL-1, IL-6, IL-8 and GM-CSF (Brennan et al., 1989, Lancet 2: 244-247). Because of its role in inflammation, TNF- ⁇ has emerged as an important inhibition target in efforts to reduce the symptoms of inflammatory disorders.
- soluble TNF- ⁇ receptors and antibodies specific for TNF- ⁇ .
- Commercial products approved for clinical use include, for example, the antibody products RemicadeTM (infliximab; Centocor, Malvern, Pa.; a chimeric monoclonal IgG antibody bearing human IgG1 constant and mouse variable regions), HumiraTM (adalimumab or D2E7; Abbott Laboratories, described in U.S. Pat. No. 6,090,382) and the soluble receptor product EnbrelTM (etancrcept, a soluble p75 TNFR2 Fc fusion protein; Immunex).
- RemicadeTM infliximab
- Centocor Centocor, Malvern, Pa.
- HumiraTM adalimumab or D2E7
- soluble receptor product EnbrelTM etancrcept, a soluble p75 TNFR2 Fc fusion protein
- TNF- ⁇ is highly expressed in inflamed synovium, particularly at the cartilage-pannus junction (DiGiovine et al., 1988, Ann. Rheum. Dis. 47: 768-772; Firestein et al., 1990, J. Immunol. 144: 3347-3353; and Saxne et al., 1988, Arthritis Rheum. 31: 1041-1045).
- TNF- ⁇ increases the levels of inflammatory cytokines IL-1, IL-6, IL-8 and GM-CSF
- TNF- ⁇ can alone trigger joint inflammation and proliferation of fibroblast-like synoviocytes (Gitter et al., 1989, Immunology 66: 196-200), induce collagenase, thereby triggering cartilage destruction (Dayer et al., 1985, J. Exp. Med. 162: 2163-2168; Dayer et al., 1986, J. Clin. Invest.
- TNF- ⁇ induces increased release of CD14+ monocytes by the bone marrow.
- Such monocytes can infiltrate joints and amplify the inflammatory response via the RANK (Receptor Activator of NF- ⁇ B)-RANKL signaling pathway, giving rise to osteoclast formation during arthritic inflammation (reviewed in Anandarajah & Richlin, 2004, Curr. Opin. Rheumatol. 16: 338-343).
- TNF- ⁇ is an acute phase protein which increases vascular permeability through its induction of IL-8, thereby recruiting macrophage and neutrophils to a site of infection. Once present, activated macrophages continue to produce TNF- ⁇ , thereby maintaining and amplifying the inflammatory response.
- TNF- ⁇ Titration of TNF- ⁇ by the soluble receptor construct etanercept has proved effective for the treatment of RA, but not for treatment of Crohn's disease.
- the antibody TNF- ⁇ antagonist infliximab is effective to treat both RA and Crohn's disease.
- the mere neutralization of soluble TNF- ⁇ is not the only mechanism involved in anti-TNF-based therapeutic efficacy. Rather, the blockade of other pro-inflammatory signals or molecules that are induced by TNF- ⁇ also plays a role (Rutgeerts et al., supra).
- the administration of infliximab apparently decreases the expression of adhesion molecules, resulting in a decreased infiltration of neutrophils to sites of inflammation.
- infliximab therapy results in the disappearance of inflammatory cells from previously inflamed bowel mucosa in Crohn's disease.
- This disappearance of activated T cells in the lamina propria is mediated by apoptosis of cells carrying membrane-bound TNF- ⁇ following activation of caspases 8,9 and then 3 in a Fas dependent manner (see Lugering et al., 2001, Gastroenterology 121: 1145-1157).
- membrane- or receptor-bound TNF- ⁇ is an important target for anti-TNF- ⁇ therapeutic approaches.
- infliximab binds to activated peripheral blood cells and lamina intestinal cells and induces apoptosis through activation of caspase 3 (sec Van den Brando et al., 2003, Gastroenterology 124: 1774-1785).
- TNF- ⁇ Intracellularly, the binding of trimeric TNF- ⁇ to its receptor triggers a cascade of signaling events, including displacement of inhibitory molecules such as SODD (silencer of death domains) and binding of the adaptor factors FADD, TRADD, TRAF2, c-IAP, RAIDD and TRIP plus the kinase RIP1 and certain caspases (reviewed by Chen & Goeddel, 2002, Science 296: 1634-1635, and by Muzio & Saccani in :Methods in Molecular Medicine: Tumor Necrosis Factor, Methods and Protocols,” Corti and Ghezzi, eds. (Humana Press, New Jersey; 2004), pp. 81 -99).
- SODD semiconductor of death domains
- the assembled signalling complex can activate either a cell survival pathway, through NF- ⁇ B activation and subsequent downstream gene activation, or an apoptotic pathway through caspase activation. Similar extracellular downstream cytokine cascades and intracellular signal transduction pathways can be induced by TNF- ⁇ in other diseases. Thus, for other diseases or disorders in which the TNF- ⁇ molecule contributes to the pathology, inhibition of TNF- ⁇ presents an approach to treatment.
- Angiogenesis plays an important role in the active proliferation of inflammatory synovial tissue. RA synovial tissue, which is highly vascularized, invades the periarticular cartilage and bone tissue and leads to joint destruction.
- VEGF Vascular endothelial growth factor
- VEGF is a secreted, heparin-binding, homodimeric glycoprotein existing in several alternate forms due to alternative splicing of its primly transcript (Leung et al., 1989, Science 246: 1306-1309).
- VEGF is also known as vascular permeability factor (VPF) due to its ability to induce vascular leakage, a process important in inflammation.
- VPF vascular permeability factor
- VEGF expression in the joints increased upon induction of the disease, and the administration of anti-VEGF antisera blocked the development of arthritic disease and ameliorated established disease (Sone et al., 2001, Biochem. Biophys. Res. Comm. 281: 562-568; Lu et al., 2000, J. Immunol. 164: 5922-5927).
- Antibodies are highly specific for their binding targets and although they are derived from nature's own defence mechanisms, antibodies face several challenges when applied to the treatment of disease inhuman patients.
- Conventional antibodies are large multi-subunit protein molecules comprising at least four polypeptide chains.
- human IgG has two heavy chains and two light chains that are disulfide bonded to form the functional antibody.
- the size of a conventional IgG is about 150 kD. Because of their relatively large size, complete antibodies (e.g., IgG, IgA, IgM, etc.) are limited in their therapeutic usefulness due to problems in, for example, tissue penetration. Considerable efforts have focused on identifying and producing smaller antibody fragments that retain antigen binding function and solubility.
- the heavy and light polypeptide chains of antibodies comprise variable (V) regions that directly participate in antigen interactions, and constant (C) regions that provide structural support and function in non-antigen-specific interactions with immune effectors.
- the antigen binding domain of a conventional antibody is comprised of two separate domains: a heavy chain variable domain (VH) and a light chain variable domain (VL: which can be either V ⁇ or V ⁇ ).
- VH heavy chain variable domain
- VL light chain variable domain
- the antigen binding site itself is formed by six polypeptide loops: three from the VH domain (H1, H2 and H3) and three from the VL domain (L1, L2 and L3). In vivo, a diverse primary repertoire of V genes that encode the VH and VL domains is produced by the combinatorial rearrangement of gene segments.
- C regions include the light chain C regions (referred to as CL regions) and the heavy chain C regions (referred to as CH1, CH2 and CH3 regions).
- CL regions the light chain C regions
- CH1, CH2 and CH3 regions the heavy chain C regions
- a number of smaller antigen binding fragments of naturally occurring antibodies have been identified following protease digestion. These include, for example, the “Fab fragment” (VL-CL-CH1-VH), “Fab′ fragment” (a Fab with the heavy chain hinge region) and “F(ab′)2 fragment” (a dimer of Fab′ fragments joined by the heavy chain hinge region).
- Recombinant methods have been used to generate even smaller antigen-binding fragments, referred to as “single chain Fv” (variable fragment) or “scFv,” consisting of VL and VH joined by a synthetic peptide linker.
- VHH domains VHH domains and retain the ability, when isolated as fragments of the VH chain, to bind antigen with high specificity
- Antigen binding single VH domains have also been identified from, for example, a library of murine VH genes amplified from genomic DNA from the spleens of immunized mice and expressed in E. coli (Ward et al, 1989, Nature 341: 544-546). Ward et al. named the isolated single VH domains “dAbs,” for “domain antibodies”.
- the term “dAb” will refer herein to a single immunoglobulin variable domain (VH, VHH or VL) polypeptide that specifically binds antigen.
- a “dAb” binds antigen independently of other V domains; however, as the term is used herein, a “dAb” can be present in a homo- or heteromultimer with other VH or VL domains where the other domains are not required for antigen binding by the dAb, i.e., where the dAb binds antigen independently of the additional VH, VHH or VL domains.
- Single immunoglobulin variable domains for example, VHH, are the smallest antigen-binding antibody unit known.
- human antibodies are preferred, primarily because they are not as likely to provoke an immune response when administered to a patient. Isolated non-camelid VH domains tend to be relatively insoluble and are often poorly expressed.
- WO 03/035694 (Muyldermans) reports that a Trp 103 Arg mutation improves the solubility of non-camelid VH domains, Davies & Riechmann, (1995, Biotechnology N.Y. 13: 475-479) also report production of a phage-displayed repertoire of camelized human VH domains and selection of clones that bind hapten with affinities in the range of 100-400 nM, but clones selected for binding to protein antigen had weaker affinities.
- the antigen binding domain of an antibody comprises two separate regions: a heavy chain variable domain (VH) and a light chain variable domain (VL: which can be either V ⁇ or V ⁇ ).
- the antigen binding site itself is formed by six polypeptide loops: three from VH domain (H1, H2 and H3) and three from VL domain (L1, L2 and L3).
- VH domain H1, H2 and H3
- VL domain L1, L2 and L3
- a diverse primary repertoire of V genes that encode the VH and VL domains is produced by the combinatorial rearrangement of gene segments.
- the VH gene is produced by the recombination of three gene segments, VH, D and JH. In humans, there are approximately 51 functional VH segments (Cook and Tomlinson, 1995, Immunol. Today, 16: 237), 25 functional D segments (Corbett et al., 1997 J. Mol.
- VH segment encodes the region of the polypeptide chain which forms the first and second antigen binding loops of the VH domain (H1 and H2), whilst the VH, D and JH segments combine to form the third antigen binding loop of the VH domain (H3).
- the VL gene is produced by the recombination of only two gene segments, VL and JL. In humans, there are approximately 40 functional V ⁇ segments (Schable and Zachau (1993) Biol. Chem.
- the VL segment encodes the region of the polypeptide chain which forms the first and second antigen binding loops of the VL domain (L1 and L2), whilst the VL and JL segments combine to form the third antigen binding loop of the VL domain (L3).
- Antibodies selected from this primary repertoire are believed to be sufficiently diverse to bind almost all antigens with at least moderate affinity.
- High affinity antibodies are produced by “affinity maturation” of the rearranged genes, in which point mutations are generated and selected by the immune system on the basis of improved binding. Analysis of the structures and sequences of antibodies has shown that five of the six antigen binding loops (H1, H2, L1, L2, L3) possess a limited number of main-chain conformations or canonical structures (Chothia and Lesk, 1987, Mol. Biol., 196; 901-917; Chothia al., 1989, Nature, 342: 877-883).
- the main-chain conformations are determined by (i) the length of the antigen binding loop, and (ii) particular residues, or types of residue, at certain key position in the antigen binding loop and the antibody framework. Analysis of the loop lengths and key residues has enabled us to predict the main-chain conformations of H1, H2, L1, L2 and L3 encoded by the majority of human antibody sequences (Chothia et al., 1992, J. Mol. Biol., 227: 799-817; Tomlinson et al., 1995, EMBO J., 14; 4628-4638; Williams et al., 1996, J. Mol. Biol., 264: 220-232).
- H3 region is much more diverse in terms of sequence, length and structure (due to the use of D segments), it also forms a limited number of main-chain conformations for short loop lengths which depend on the length and the presence of particular residues, or types of residue, at key positions in the loop and the antibody framework (Martin et al., 1996, J. Mol. Biol, 263: 800-815; Shirai et al., 1996, FEBS Letters, 399: 1-8).
- Bispecific antibodies comprising complementary pairs of VH and VL regions are known in the art. These bispecific antibodies must comprise two pairs of VH and VLs, each VH/VL pair binding to a single antigen or epitope. Methods described involve hybrid hybridomas (Milstein & Cuello, Nature, 1983, 305:537-40), minibodies (Hu et al., 1996, Cancer Res 30 56:3055-3061), diabodies (Holliger et al., 1993, Proc. Natl. Acad. Sci. USA 90, 6444-6448; WO 94/13804), chelating recombinant antibodies (CRAbs; Neri et al., 1995, J. Mol. Biol.
- each antibody species comprises two antigen-binding sites, each fashioned by a complementary pair of VH and VL domains. Each antibody is thereby able to bind to two different antigens or epitopes at the same time, with the binding to EACH antigen or epitope mediated by a VH and its complementary VL domain.
- cross-reactive antibodies have been so described, usually where the two antigens are related in sequence and structure, such as hen egg white lysozyme and turkey lysozyme (McCafferty et al., WO 92/01047) or to free hapten and to hapten conjugated to carrier (Griffiths et al., 1994, EMBO J 13:14 3245-60).
- WO 02/02773 (Abbott Laboratories) describes antibody molecules with “dual specificity”.
- the antibody molecules referred to are antibodies raised or selected against multiple antigens, such that their specificity spans more than a single antigen.
- Each complementary VH/VL pair in the antibodies of WO 02/02773 specifies a single binding specificity for two or more structurally related antigens; the VH and VL domains in such complementary pairs do not each possess a separate specificity.
- the antibodies thus have a broad single specificity which encompasses two antigens, which are structurally related.
- natural autoantibodies have been described that are polyreactive (Casali & Nolkins, 1989, Ann. Rev. Immunol. 7, 515-531), reacting with at least two (usually more) different antigens or epitopes mat are not structurally related.
- Protein engineering methods have been suggested that may have a bearing on this.
- a catalytic antibody could be created with a binding activity to a metal ion through one variable domain, and to a hapten (substrate) through contacts with the metal ion and a complementary variable domain (Barbae et al, 1993, Proc. Natl. Acad. Sci USA 90,6385-6389).
- the binding and catalysis of the substrate is proposed to require the binding of the metal ion (second antigen).
- the binding to the VH/VL pairing relates to a single but multi component antigen.
- camel heavy chain single domains are unusual in that they are derived from natural camel antibodies which have no light chains, and indeed the heavy chain single domains are unable to associate with camel light chains to form complementary VH and VL pairs.
- Single heavy chain variable domains have also been described, derived from natural antibodies which are normally associated with light chains (from monoclonal antibodies or from repertoires of domains; see EP-A-0368684). These heavy chain variable domains have been shown to interact specifically with one or more related antigens but have not been combined with other heavy or light chain variable domains to create a ligand with specificity for two or more different antigens. Furthermore, these single domains have been shown to have a very short in viva half-life. Therefore, such domains are of limited therapeutic value.
- Human/mouse chimeric antibodies have been created in which antibody variable region sequences from the mouse genome are combined with antibody constant region sequences from the human genome.
- the chimeric antibodies exhibit the binding characteristics of the parental mouse antibody, and the effector functions associated with the human constant region.
- the antibodies are produced by expression in a host cell, including for example Chinese Hamster Ovary (CHO). NS0 myeloma cells, COS cells and SP2 cells.
- Such chimeric antibodies have been used inhuman therapy, however antibodies to these chimeric antibodies have been produced by the human recipient. Such anti-chimeric antibodies are detrimental to continued therapy with chimeric antibodies.
- human monoclonal antibodies are expected to be an improvement over mouse monoclonal antibodies for in vivo human therapy. From work done with antibodies from Old World primates (rhesus monkeys and chimpanzees) it has been postulated mat these non-human primate antibodies will be tolerated in humans because they are structurally similar to human antibodies (Ehrlich PH et al., 1988, Human and primate monoclonal antibodies for in vivo therapy. Clin Chem. 34:9 pg 1681-1688).
- EP 0 605 442 discloses chimeric antibodies which bind human antigens. These antibodies comprise the whole variable region from an Old World monkey and the constant region of a human or chimpanzee antibody.
- One of the advantages suggested in this reference for these constructs is the ability to raise antibodies in Old World monkeys to human antigens which are less immunogenic in humans compared with antibodies raised in a mouse host.
- New World primates comprise at least 53 species commonly divided into two families, the Callithricidae and Cebidae.
- the Callithricidae consist of marmosets and tamarins.
- the Cebidae includes the squirrel monkey, titi monkey, spider monkey, woolly monkey, capuchin, uakaris, sakis, night or owl monkey and the howler monkey.
- Evolutionarily distant primates such as New World primates, are not only sufficiently different from humans to allow antibodies against human antigens to be generated, but are sufficiently similar lo humans to have antibodies similar to human antibodies so that the host does not generate an anti-antibody immune response when such primate-derived antibodies are introduced into a human.
- the present invention provides a chimeric antibody polypeptide comprising an antigen binding site, wherein the antigen binding site comprises a human variable domain having at least one New World Primate CDR.
- the present invention provides a method of producing an antibody polypeptide according to the first aspect of the invention, the method comprising the steps of:
- the present invention provides a chimeric domain antibody (dAb) which binds human TNF- ⁇ , the dAb comprising an immunoglobulin heavy or light chain variable domain, wherein said variable domain comprises at least one New World Primate CDR.
- dAb chimeric domain antibody
- the present invention provides a pharmaceutical composition
- a pharmaceutical composition comprising an effective amount of an antibody polypeptide according to the first or third aspects of the invention, together with a pharmaceutically acceptable carrier or diluent.
- FIG. 1 shows the amino acid (SEQ ID No:6) and nucleotide sequence (SEQ ID No:5) of the acceptor dAb.
- FIG. 2 shows the nucleotide and amino acid sequences of eleven (11) marmoset and six. (6) Owl monkey V ⁇ gene segments.
- FIG. 3 shows the acceptor dAb amino acid and nucleotide sequence (both strands).
- the restriction digest sites for Kpn I and San DI which excises a region including the CDR2 is indicated in the figure.
- CDR2 residues removed are indicated in underline.
- FIG. 4 shows sequence alignments showing oligonucleotides used during cloning and final sequence confirmation of the nucleotide (A) and amino acid (B) sequences shown in FIG. 2 .
- FIG. 5 demonstrates the ability of CDR2-grafted dAbs to inhibit the binding of TNF to recombinant TNF receptor.
- FIG. 6 demonstrates the improved ability of Compounds 100 and 123 to neutralise the cytotoxic activity of TNF on mouse L929 fibroblasts relative to Compound 145.
- the present invention provides a chimeric antibody polypeptide comprising an antigen binding site, wherein the antigen binding site comprises a human variable domain having at least one New World Primate CDR.
- the present invention provides a chimeric domain antibody (dAb) which binds human TNF- ⁇ , the dAb comprising an immunoglobulin heavy or light chain variable domain, wherein said variable domain comprises at least one New World Primate CDR.
- dAb chimeric domain antibody
- the present invention provides a pharmaceutical composition
- a pharmaceutical composition comprising an effective amount of an antibody polypeptide according to the first or third aspects of the invention, together with a pharmaceutically acceptable carrier or diluent.
- the human variable domain comprises at least one human framework region having an amino acid sequence encoded by a human germline antibody gene segment, or an amino acid sequence comprising up to 5 amino acid differences relative to the amino acid sequence encoded by the human germline antibody gene segment.
- the human variable domain preferably comprises four human framework regions, FR1, FR2, FR3 and FR4 having amino acid sequences encoded by a human germline antibody gene segment, or the amino acid sequences which collectively contain up to 10 ammo acid differences relative to the amino acid sequences encoded by said human germline antibody gene segment.
- the human germline antibody gene segment selected from the group consisting of DP47, DP45, DP48 and DPK9.
- the New World Primate CDR may be any CDR, however, it is preferred that the New World Primate CDR is CDR2.
- the New World Primate CDR is CDR1 or CDR3.
- New World Primate CDR sequence is a germline New World Primate CDR sequence.
- the antibody polypeptide of the present invention is preferably selected from a dAb, scFv, Fab, (Fab′) 2 , Fv, disulphide bonded Fv, IgG, and a diabody.
- the antibody polypeptide of the present invention is preferably directed against TNF- ⁇ .
- the human variable domain amino acid sequence comprises a Kpn1 restriction site spaced from a SanD1 restriction site, said CDR of the human variable domain being between the restriction sites.
- New World Primate CDR sequence is obtainable from New World Primate DNA by PCR using primer pair VK1BL (SEQ ID No:11)/VK1BL35a (SEQ ID No:12) or primer pair VK1BL (SEQ ID No:11/VK1BL35b (SEQ ID No:13).
- the present invention also provides a chimeric domain antibody (dAb) which binds to human TNF- ⁇ , wherein the dAb is a human dAb that binds human TNF- ⁇ in which at least one of the CDRs is replaced with the corresponding CDR from a New World Primate.
- dAb chimeric domain antibody
- the present invention also provides a method of producing an antibody polypeptide according to the first aspect of the invention, the method comprising the steps of:
- step (ii) said CDR of said human variable domain is replaced by said donor New World Primate CDR using restriction digestion and annealing of an oligonucleotide encoding the donor CDR into the acceptor sequence.
- the method further comprises affinity maturing the variable domain produced in step (ii).
- New World Primate CDR refers to a CDR sequence obtained from a New World Primate.
- the term encompasses modification of 1, 2 or 3 ammo acids within the sequence which may be used to achieve improved antigen binding characteristics or lower immunogenicity. The term does not, however, extend to cover modifications which result in the New World Primate CDR sequence being identical to a human CDR sequence.
- human framework region refers to a framework region obtained from a human or a human framework region having an amino acid sequence encoded by a human germline antibody gene segment, or an amino acid sequence comprising up to 5 amino acid differences relative to the amino acid sequence encoded by the human germline gene segment.
- the term also encompasses modification of the amino acid sequence of the framework region in order to obtain improved antigen binding characteristics or lower immunogenicity such as disclosed in U.S. Pat. No. 4,816,567, U.S. Pat. No. 5,585,089 and US 20030039649 the disclosures of which are incorporated herein by reference in their entirety. Typically where modifications are made the total number of residues changed will be 10 or less collectively over the framework regions.
- variable domain comprises four framework regions, wherein at least one framework region comprises an amino acid sequence derived from a corresponding framework region encoded by a human germline immunoglobulin gene.
- the four framework regions comprise amino acid sequences derived from corresponding framework regions encoded by human germline immunoglobulin genes.
- the human germline immunoglobulin gene is selected from the group consisting of DP47, DP45, DP48 and DPK9.
- domain as used herein is meant a folded protein structure which retains its tertiary structure independently of the rest of the protein. Generally, domains are responsible for discrete functional properties of proteins, and in many cases may be added, removed or transferred to other proteins without loss of function of the remainder of the protein and/or of the domain.
- immunoglobulin or antibody “variable domain” as used herein is a term of art, and includes a folded polypeptide domain comprising sequences characteristic of immunoglobulin or antibody heavy or light chain variable domains and which specifically binds an antigen.
- immunoglobulin refers to a family of polypeptides which retain the immunoglobulin fold characteristic of antibody molecules, which contains two ⁇ sheets and, usually, a conserved disulphide bond.
- Members of the immunoglobulin superfamily are involved in many aspects of cellular and non-cellular interactions in vivo, including widespread roles in the immune system (for example, antibodies, T-cell receptor molecules and the like), involvement in cell adhesion (for example the ICAM molecules) and intracellular signalling (for example, receptor molecules, such as the PDGF receptor).
- the present invention is applicable to all immunoglobulin superfamily molecules which possess binding domains.
- the present invention relates to antibody polypeptides.
- New World primates comprise at least 53 species commonly divided into two families, the Callithricidae and Cebidae.
- the Callithricidae consist of marmosets and tamarins.
- the Cebidae includes the squirrel monkey, titi monkey, spider monkey, woolly monkey, capuchin, uakaris, sakis, night or owl monkey and the howler monkey.
- Evolutionarily distant primates such as New World primates, are not only sufficiently different from humans to allow antibodies against human antigens to be generated, but are sufficiently similar to humans to have antibodies similar to human antibodies so that the host does not generate an anti-antibody immune response when such primate-derived antibodies are introduced into a human.
- the New World primate CDR is from the family Callithricidae.
- the New World primate CDR is selected from the group consisting of marmosets, tamarins, squirrel monkey, titi monkey, spider monkey, woolly monkey, capuchin, uakaris, sakis, night or owl monkey and the howler monkey. More preferably, the New World primate is a marmoset.
- the at least one New World primate CDR is substantially identical to a CDR encoded by a New World primate germline immunoglobulin gene.
- antibody as used herein, is intended to refer to immunoglobulin molecules comprised of two heavy chains or immunoglobulin molecules comprised of four polypeptide chains, two heavy (H) chains and two light (L) chains inter-connected by disulfide bonds.
- Each heavy chain is comprised of a heavy chain variable region (HCVR or V H ) and a heavy chain constant region.
- the heavy chain constant region comprises three domains, C H 1, C H 2 and C H 3.
- Each light chain is comprised of a light chain variable region (LCVR or V L ) and a light chain constant region.
- the light chain constant region is comprised of one domain, C L .
- V H and V L regions can be further subdivided into regions of hypervariability, termed complementarity determining regions (CDR), interspersed with regions that are more conserved, termed framework regions (PR).
- CDR complementarity determining regions
- PR framework regions
- Each V H and V L is composed of three CDRs and four FRs, arranged from amino-terminus to carboxy-terminus in the following order: FR1, CDR1, FR2, CDR2, FR3, CDR3, FR4.
- antibody polypeptide refers to a polypeptide comprising one or more components or derivatives of an immunoglobulin that exhibit the ability to bind to an antigen. It has been shown that the antigen-binding function of an antibody can be performed by fragments of a full length antibody.
- binding fragments encompassed within the term “antibody polypeptide” include (i) a Fab fragment, a monovalent fragment consisting of the V L , V H , C L and C H 1 domains; (ii) a F(ab′) 2 fragment, a bivalent fragment comprising two Fab fragments linked by a disulfide bridge at the hinge region; (iii) a Fd fragment consisting of the V H and C H 1 domains; (iv) a Fv fragment consisting of the V L and V H domains of a single arm of an antibody, (v) a dAb fragment (Ward et al, 1989, Nature 341:544-546) which consists of a single V H domain, or a V L domain (van den Beucken et al, 2001, J.
- V L and V H are coded by separate genes, they can be joined, using recombinant methods, by a synthetic linker that enables them to be made as a single protein chain in which the V L and V H regions pair to form monovalent molecules (known as single chain Fv (scFv); (see eg Bird et al., 1988, Science 242:423-426 and Huston et al., 1988 Proc. Natl. Acad. Sci. USA 85:5879-5883).
- scFv single chain Fv
- single chain Fvs are also intended to be encompassed within the term “antigen-binding portion” of an antibody.
- Other forms of single chain Fvs and related molecules such as diabodies or triabodies are also encompassed.
- Diabodies are bivalent antibodies in which V H and V L domains are expressed on a single polypeptide chain, but using a linker that is too short to allow for pairing between the two domains on the same chain, thereby forcing the domains to pair with complementary domains of another chain and creating two antigen binding sites (see e.g., Holliger, et al., 1993, Proc. Natl. Acad. Sci. USA, 90:6444-6448; Poljak, et al., 1994, Structure, 2:1121-1123).
- the antibody polypeptide is selected from the group consisting of a dAb, scFv, Fab, F(ab′) 2 , Fv, disulphide bonded Fv, a diabody and IgG.
- the antibody polypeptide further comprises a human or non-human primate constant region sequence.
- non-human primates include, but are not limited to, chimpanzees, oranguatangs and baboons.
- the constant region sequence is preferably obtained from a human or non-human primate immunoglobulin sequence.
- the primate sequence may be a New World primate or an Old World primate sequence. Suitable Old World primates include chimpanzee, or other hominid ape eg. gorilla or orangutan, which because of their close phylogenetic proximity to humans, share a high degree of homology with the human constant region sequence. Sequences which encode for human or primate constant regions are available from databases including e.g. The National Centre for Biotechnology Information protein and nucleotide databases, The Kabat Database of Sequences of Proteins of Immunological Interest.
- the antibody polypeptide is a domain antibody (dAb).
- Domain antibodies are small functioning binding units of antibodies and correspond to the variable regions of either the heavy (V H ) or light (V L ) chains of antibodies. Domain antibodies have a molecular weight of approximately 13 kDa, or less than one tenth the size of a full antibody.
- Antibody light chains are referred to as either kappa or lambda light chains and the heavy chains as gamma, mu, delta, alpha or epsilon.
- the variable region gives the antibody its specificity.
- regions of hypervariability otherwise known as complementarity determining regions (CDRs) which are flanked by more conserved regions referred to as framework regions.
- CDRs complementarity determining regions
- framework regions Within each variable region are three CDRs and four framework regions.
- domain antibodies are well expressed in bacterial, yeast and mammalian systems. Their small size allows for higher molar quantities per gram or product, thus providing a significant increase in potency per dose.
- domain antibodies can be used as a building block to create therapeutic products such as multiple targeting dAbs in which a construct containing two or more variable domains bind to two or more therapeutic targets, or dAbs targeted for pulmonary or oral administration.
- an increase in binding is demonstrated by a decrease in K D (k off /k on ) for the antibody or antigen binding portion thereof.
- An increase in potency is demonstrated in biological assays.
- assays that can be used to measure the potency of the antibody or antigen-binding portion thereof include the TNF ⁇ -induced L929 cytotoxicity neutralisation assay, IL-12-induced human PHA-activated peripheral blood mononuclear cell (PBMC) proliferation assay, and RANKL mediated osteoclast differentiation of mouse splenocytes (Stem, 1990, Proc. Natl. Acad. Sci.
- the CDR sequences may be obtained from several sources, for example, databases e.g. The National Centre for Biotechnology Information protein and nucleotide databases www.ncbi.nlm.nih.gov, The Kabat Database of Sequences of Proteins of Immunological Interest www.kabatdatabase.com, or the IMGT database www.imgt.cines.fr.
- the CDR regions can be predicted from the V H and V L domain repertoire (see for example Kabat and Wu, 1971, Ann. NY Acad. Sci. 190:382-393).
- the CDR sequence may be a genomic DNA or a cDNA.
- the preferred method of the present invention involves replacement of the CDR2 in the variable region domain via primer directed mutagenesis. This method consists of annealing a synthetic oligonucleotide encoding a desired mutations to a target region where it serves as a primer for initiation of DNA synthesis in vitro, extending the oligonucleotide by a DNA polymerase to generate a double-stranded DNA that carries the desired mutations, and ligating and cloning the sequence into an appropriate expression vector.
- variable domain sequence into which the CDR is grafted is the “dAb acceptor sequence” (designated Compound 128; SEQ ID No:6) provided in FIG. 1 .
- chimeric is meant that the antibody polypeptide or domain antibody includes sequences from more than one species.
- the anti-human TNF- ⁇ dAb according to the invention can be used to detect human TNF- ⁇ for example in a biological sample, such as serum or plasma using a conventional immunoassay, such as an enzyme linked immunosorbent assay (ELISA), a radioimmunoassay (RIA) or tissue immunohistochemistry.
- a biological sample such as serum or plasma
- a conventional immunoassay such as an enzyme linked immunosorbent assay (ELISA), a radioimmunoassay (RIA) or tissue immunohistochemistry.
- ELISA enzyme linked immunosorbent assay
- RIA radioimmunoassay
- tissue immunohistochemistry tissue immunohistochemistry.
- the anti-human TNF- ⁇ dAb according to the invention can be assayed in biological fluids by a competition immunoassay using recombinant human TNF- ⁇ standards label led with a detectable substance and an unlabelled anti-human TNF- ⁇ antibody.
- the anti-human TNF- ⁇ dAb according to the invention may also be used to detect TNF- ⁇ from species other than humans eg. chimpanzee, marmoset, rhesus, mouse, pig.
- the anti-human TNF- ⁇ dAb according to the invention may also be used in cell culture applications where it is desired to inhibit TNF- ⁇ activity.
- the invention also provides a method for treating a disorder characterised by human TNF- ⁇ activity in a human subject, comprising administering to the subject a pharmaceutical composition according to the second aspect of the invention.
- a disorder characterised by human TNF- ⁇ activity is intended to include diseases and other disorders in which the presence of TNF- ⁇ in a subject suffering from the disorder has been shown to be or is suspected of being either responsible for the pathophysiology of the disorder or a factor which contributes to a worsening of the disorder.
- the disorder characterised by human TNF- ⁇ activity is selected from the group consisting of inflammation, inflammatory diseases, sepsis, including septic shock, endotoxic shock, gram negative sepsis and toxic shock syndrome; autoimmune disease, including rheumatoid arthritis, rheumatoid spondylitis, osteoarthritis and gouty arthritis, allergy, multiple sclerosis, autoimmune diabetes, autoimmune uveitis and nephrotic syndrome; infectious disease, including fever and myalgias due to infection and cachexia secondary to infection; graft versus host disease; tumour growth or metastasis; pulmonary disorders including adult respiratory distress syndrome, shock lung, chronic pulmonary inflammatory disease, pulmonary sarcoidosis, pulmonary fibrosis and silicosis; inflammatory bowel disorders including Crohn's disease and ulcerative colitis; cardiac disorders; inflammatory bone disorders, hepatitis, coagulation disturbances, burns, reperfusion injury, keloid formation and scar tissue formation
- the invention provides a pharmaceutical composition
- a pharmaceutical composition comprising an effective amount of the antibody polypeptide according to the first aspect of the invention or a chimeric domain antibody according to the third aspect of the invention, together with a pharmaceutically acceptable carrier or diluent.
- a “pharmaceutically acceptable carrier” includes any and all solvents, dispersion media, coatings, antibacterial and antifungal-agents, isotonic and absorption delaying agents, and the like which are physiologically compatible.
- pharmaceutically acceptable carriers include one or more of water, saline, phosphate buffered saline, dextrose, glycerol, ethanol, and the like as well as combinations thereof.
- isotonic agents for example, sugars, polyalcohols such as mannitol, sorbitol, or sodium chloride in the composition.
- Pharmaceutically acceptable substances such as welling or minor amounts of auxiliary substances such as wetting or emulsifying agents, preservatives or buffers.
- the composition may be in a variety of forms, including liquid, semi-solid and solid dosage forms, such as liquid solutions (eg injectable and infusible solutions), dispersions or suspensions, tablets, pills, powders, liposomes and suppositories.
- the composition is in the form of an injectable solution for immunization.
- the administration may be intravenous, subcutaneous, intraperitoneal, intramuscular, transdermal, intrathecal, and intra-arterial.
- compositions typically must be sterile and stable under the conditions of manufacture and storage.
- the compositions can be formulated as a solution, microemulsion, dispersion, liposome, or other ordered structure suitable to high drug concentration.
- Sterile injectable solutions can be prepared by incorporating the active compound (i.e. antibody polypeptide) into the required amount in an appropriate solvent with one or a combination of ingredients listed above, followed by filtered sterilisation.
- composition may also be formulated as a sterile powder for the preparation of sterile injectable solutions.
- the proper fluidity of a solution can be maintained by for example, use of a coating such as lecithin and/or surfactants.
- the active compound may be prepared with a carrier that will protect the compound against rapid release, such as a controlled release formulation, including implants, transdermal patches, and microencapsulated delivery systems.
- a carrier that will protect the compound against rapid release, such as a controlled release formulation, including implants, transdermal patches, and microencapsulated delivery systems.
- Compatible polymers may be used such as ethylene vinyl acetate, polyanhydrides, polyglycolic acid, collagen, polyorthoesters and polylactic acid.
- composition may also be formulated for oral administration.
- the antibody polypeptide may be enclosed in a hard or soft shell gelatin capsule, compressed into tablets, or incorporated directly into the subject's diet.
- composition may also be formulated for rectal administration.
- Supplementary active compounds can also be incorporated into the composition.
- the antibody polypeptide may be co-formulated with and/or co-administered with one or more additional therapeutic agents eg. anti-inflammatory compounds, soluble TNF- ⁇ receptor or a chemical agent that inhibits human TNF- ⁇ production, or antibodies that bind other targets such as cytokines or cell surface molecules.
- additional therapeutic agents eg. anti-inflammatory compounds, soluble TNF- ⁇ receptor or a chemical agent that inhibits human TNF- ⁇ production, or antibodies that bind other targets such as cytokines or cell surface molecules.
- a soluble immunochemical reagent such as protein A, C, G or L.
- An effective amount may include a therapeutically effective amount or prophylactically effective amount of the antibody polypeptide of the invention.
- a therapeutically effective amount refers to an amount effective at dosages and for periods of time necessary, to achieve the desired therapeutic result.
- a prophylactically effective amount refers to an amount effective, at dosages and for periods of lime necessary, to achieve the desired prophylactic result.
- composition is administered to mammals, preferably humans or primates.
- Marmoset (genus Callidirix , species unknown) and Owl monkey ( Aotus trivirgatus ) genomic DNA were obtained from the European Collection of Cell Cultures (ECACC), catalogue numbers 85011419 and 90110510 respectively. Marmoset DNA was derived from cell line B95-8 while Owl monkey DNA came from cell line OMK 637-69.
- V ⁇ leader sequences and recombination signal sequences were derived from Walter and Tomlinson, Antibody Engineering: A Practical Approach (1996).
- the primers used for amplification of germline V ⁇ DNA were as follows:
- Primer VK1BL AATCKCAGGTKCCAGATG (SEQ ID No: 11) Primer VK1BL35a GTTYRGGTKKGTAACACT (SEQ ID No: 12) Primer VK1BL35b ATGMCTTGTWACACTGTG (SEQ ID No: 13)
- Genomic PCR (30 cycles) was performed using Taq polymerase with either primer pair VK1BLxVK1BL35a or VK1LxVK1BL35b. There was overlap between the sequences cloned and the two primer sets used.
- PCR products were cloned into Invitrogen's TOPO TA cloning kit (Cat No K4500-01) and sequenced with M13 forward and pUC reverse primers. Sequence was confirmed in forward and reverse directions. In order to further confirm key sequences were not subject, to PCR errors, the PCR and cloning process was repeated twice for marmoset sequences. Nucleotide (SEQ ID Nos:14-24 and SEQ ID Nos:36-41) and amino acid (SEQ ID Nos:25-35 and SEQ ID Nos:42-47) sequences are given in FIG. 2 . Marmoset sequences 1, 2 and 3 were confirmed. Sequences 4, 5, 6, 7 and 8 were seen only in the initial PCR. Sequences 9, 10 and 11 were seen only in the repeat (i.e. second) PCR and cloning.
- YAATKLQS (SEQ ID No:1) from Owl monkey sequence 1 (SEQ ID No:42), YEASSLQS (SEQ ID No:2) from Owl monkey sequence 2 (SEQ ID No:43), YEASKLQS (SEQ ID No:3) from Marmoset sequence 1 (SEQ ID No:25), and YSASNLET (SEQ ID No:4) from Marmoset sequence 2 (SEQ ID No:26), were chosen from the amino acid sequences shown in FIG. 2 as indicated.
- YYASSLQS (SEQ ID No:48) was found to be identical to GI6176295 an Aotus nancymaae (Ma's night monkey) cDNA sequence, all other sequences were unique.
- acceptor variable region (anti-TNF domain antibody) sequence in the expression vector was digested (25 ⁇ g) sequentially with KpnI and SanDI which excises the majority of FR2 as well as CDR2 as indicated on the restriction digest map. The vector was then gel purified to remove the excised wild-type FR2 and CDR2 sequence.
- Oligo annealing was performed by incubating oligo pairs (500 pmol of each as shown in FIGS. 4A and 4B ) at 95° C. for 5 minutes followed by 65° C. for 5 minutes and then allowed to reach room temperature slowly on a hot block. Overlaps were then filled in during a Klenow reaction in the presence of dNTPs.
- the marmoset CDR-grafted dAb Compound 145 (SEQ ID No:7) was affinity matured by constructing 14 separate libraries, each a diversification of the sequence of SEQ ID No:7 at a single amino acid residue. The selected residues are shown shaded below.
- dAbs diversified in the 14 selected positions were tested for the ability to inhibit the binding of TNF to recombinant TNF receptor 1 (p55). Briefly, Maxisorp plates were incubated overnight with 30 mg/ml anti-human Fc mouse monoclonal antibody (Zymed, San Francisco, USA). The wells were washed with phosphate buffered saline (PBS) containing 0.05% Tween-20 and then blocked with 1% BSA in PBS before being incubated with 100 ng/ml TNF receptor 1 Fc fusion protein (R&D Systems, Minneapolis, USA). Each dAb was mixed with TNF which was added to the washed wells at a final concentration of 10 ng/ml.
- PBS phosphate buffered saline
- TNF binding was detected with 0.2 mg/ml biotinylated anti-TNF antibody (HyCult biotechnology, Uben, Netherlands) followed by 1 in 500 dilution of horse radish peroxidase labelled streptavidin (Amersham Biosciences, UK) and then incubation with TMB substrate (KPL, Gaithersburg, USA). The reaction was stopped by the addition of HCl and the absorbance was read at 450 nm. Anti-TNF dAb activity lead to a decrease in TNF binding and therefore a decrease in absorbance compared with the TNF only control ( FIG. 5 ).
- Anti-TNF dAbs identified by the minilibrary diversification approach including Compounds 100 (SEQ ID No:9) and 123 (SEQ ID No:8), were also tested for the ability to neutralise the cytotoxic activity of TNF on mouse L929 fibroblasts (Evans, T., 2000, Molecular Biotechnology 15, 243-248). Briefly, L929 cells plated in microtitre plates were incubated overnight, with anti-TNF dAb, 100 pg/ml TNF and 1 mg/ml actinomycin D (Sigma, Poole, UK).
Abstract
Description
- The present invention relates to engineered antibody polypeptides. More particularly, the present invention provides antibody polypeptides comprising an antigen binding site, wherein the antigen binding site comprises a human variable domain having at least one New World Primate CDR. In particular the present invention relates to antibody polypeptides directed against TNF-α.
- As the name implies, Tumor Necrosis Factor-α (TNF-α) was originally described as a molecule having anti-tumor properties, but the molecule was subsequently found to play key roles in other processes, including a prominent role in mediating inflammation and autoimmune disorders. TNF-α is a key proinflammatory cytokine in inflammatory conditions including, for example, rheumatoid arthritis (RA), Crohn's disease, ulcerative colitis and other bowel disorders, psoriasis, toxic shock, graft versus host disease and multiple sclerosis. The pro-inflammatory actions of TNF-α result in tissue injury, such as inducing procoagulant activity on vascular endothelial cells (Pober, et al., 1986, J. Immunol. 136:1680-1687), increasing the adherence of neutrophils and lymphocytes (Pober, et al., 1987, J. Immunol. 138:3319-3324), and stimulating the release of platelet activating factor from macrophages, neutrophils and vascular endothelial cells (Camussi, et al., 1987, J. Exp. Med. 166:1390-1404). TNF-α is synthesized as a 26 kD transmembrane precursor protein with an intracellular tail that is cleaved by a TNF-α-converting metalloproteinase enzyme and then secreted as a 17 kD soluble protein. The active form consists of a homotrimer of the 17 kD monomers which interacts with two different cell surface receptors, p55 TNFR1 and p75 TNFR2. There is also evidence that the cell surface bound precursor form of TNF-α can mediate some biological effects of the factor. Most cells express both p55 and p75 receptors which mediate different biological functions of the ligand. The p75 receptor is implicated in triggering lymphocyte proliferation, and the p55 receptor is implicated in TNF-mediated cytotoxicity, apoptosis, antiviral activity, fibroblast proliferation and NT-κB activation (see Locksley et al., 2001, Cell 104: 487-501). The TNF receptors are members of a family of membrane proteins including the NGF receptor, Fas antigen, CD27, CD30, CD40, Ox40 and the receptor for the lymphotoxin α/β heterodimer. Binding of receptor by the homotrimer induces aggregation of receptors into small clusters of two or three molecules of either p55 or p75. TNF-α is produced primarily by activated macrophages and T lymphocytes, but also by neutrophils, endothelial cells, keratinocytes and fibroblasts during acute inflammatory reactions. TNF-α is at the apex of the cascade of pro-inflammatory cytokines (Reviewed in Feldmann & Maini, 2001, Ann. Rev. Immunol. 19: 163-196). This cytokine induces the expression or release of additional proinflammatory cytokines, particularly IL-1 und IL-6 (see, for example, Rutgeerts et al., 2004, Gastroenterology 126: 1593-1610). Inhibition of TNF-α inhibits the production of inflammatory cytokines including IL-1, IL-6, IL-8 and GM-CSF (Brennan et al., 1989, Lancet 2: 244-247). Because of its role in inflammation, TNF-α has emerged as an important inhibition target in efforts to reduce the symptoms of inflammatory disorders. Various approaches to inhibition of TNF-α for the clinical treatment of disease have been pursued, including particularly the use of soluble TNF-α receptors and antibodies specific for TNF-α. Commercial products approved for clinical use include, for example, the antibody products Remicade™ (infliximab; Centocor, Malvern, Pa.; a chimeric monoclonal IgG antibody bearing human IgG1 constant and mouse variable regions), Humira™ (adalimumab or D2E7; Abbott Laboratories, described in U.S. Pat. No. 6,090,382) and the soluble receptor product Enbrel™ (etancrcept, a soluble p75 TNFR2 Fc fusion protein; Immunex). The role of TNF-α in inflammatory arthritis is reviewed in, for example, Li & Schwartz, 2003, Springer Semin. Immunopathol. 25: 19-33. In RA, TNF-α is highly expressed in inflamed synovium, particularly at the cartilage-pannus junction (DiGiovine et al., 1988, Ann. Rheum. Dis. 47: 768-772; Firestein et al., 1990, J. Immunol. 144: 3347-3353; and Saxne et al., 1988, Arthritis Rheum. 31: 1041-1045). In addition to evidence that TNF-α increases the levels of inflammatory cytokines IL-1, IL-6, IL-8 and GM-CSF, TNF-α can alone trigger joint inflammation and proliferation of fibroblast-like synoviocytes (Gitter et al., 1989, Immunology 66: 196-200), induce collagenase, thereby triggering cartilage destruction (Dayer et al., 1985, J. Exp. Med. 162: 2163-2168; Dayer et al., 1986, J. Clin. Invest. 77: 645-648), inhibit proteoglycan synthesis by articular chondrocytes (Saklatvala, 1986, Nature 322: 547-548; Saklatvala et al., 1985, J. Exp. Med. 162; 1208-1222) and can stimulate osteoclastogenesis and bone resorption (Abu-Amer et al., 2000, J. Biol. Chem., 275: 27307-27310; Bertolini et al., 1986, Nature 319: 516-518). TNF-α induces increased release of CD14+ monocytes by the bone marrow. Such monocytes can infiltrate joints and amplify the inflammatory response via the RANK (Receptor Activator of NF-κB)-RANKL signaling pathway, giving rise to osteoclast formation during arthritic inflammation (reviewed in Anandarajah & Richlin, 2004, Curr. Opin. Rheumatol. 16: 338-343). TNF-α is an acute phase protein which increases vascular permeability through its induction of IL-8, thereby recruiting macrophage and neutrophils to a site of infection. Once present, activated macrophages continue to produce TNF-α, thereby maintaining and amplifying the inflammatory response. Titration of TNF-α by the soluble receptor construct etanercept has proved effective for the treatment of RA, but not for treatment of Crohn's disease. In contrast, the antibody TNF-α antagonist infliximab is effective to treat both RA and Crohn's disease. Thus, the mere neutralization of soluble TNF-α is not the only mechanism involved in anti-TNF-based therapeutic efficacy. Rather, the blockade of other pro-inflammatory signals or molecules that are induced by TNF-α also plays a role (Rutgeerts et al., supra). For example, the administration of infliximab apparently decreases the expression of adhesion molecules, resulting in a decreased infiltration of neutrophils to sites of inflammation. Also, infliximab therapy results in the disappearance of inflammatory cells from previously inflamed bowel mucosa in Crohn's disease. This disappearance of activated T cells in the lamina propria is mediated by apoptosis of cells carrying membrane-bound TNF-α following activation of
caspases - Antibody Polypeptides
- Antibodies are highly specific for their binding targets and although they are derived from nature's own defence mechanisms, antibodies face several challenges when applied to the treatment of disease inhuman patients. Conventional antibodies are large multi-subunit protein molecules comprising at least four polypeptide chains. For example, human IgG has two heavy chains and two light chains that are disulfide bonded to form the functional antibody. The size of a conventional IgG is about 150 kD. Because of their relatively large size, complete antibodies (e.g., IgG, IgA, IgM, etc.) are limited in their therapeutic usefulness due to problems in, for example, tissue penetration. Considerable efforts have focused on identifying and producing smaller antibody fragments that retain antigen binding function and solubility. The heavy and light polypeptide chains of antibodies comprise variable (V) regions that directly participate in antigen interactions, and constant (C) regions that provide structural support and function in non-antigen-specific interactions with immune effectors. The antigen binding domain of a conventional antibody is comprised of two separate domains: a heavy chain variable domain (VH) and a light chain variable domain (VL: which can be either Vκ or Vλ). The antigen binding site itself is formed by six polypeptide loops: three from the VH domain (H1, H2 and H3) and three from the VL domain (L1, L2 and L3). In vivo, a diverse primary repertoire of V genes that encode the VH and VL domains is produced by the combinatorial rearrangement of gene segments. C regions include the light chain C regions (referred to as CL regions) and the heavy chain C regions (referred to as CH1, CH2 and CH3 regions). A number of smaller antigen binding fragments of naturally occurring antibodies have been identified following protease digestion. These include, for example, the “Fab fragment” (VL-CL-CH1-VH), “Fab′ fragment” (a Fab with the heavy chain hinge region) and “F(ab′)2 fragment” (a dimer of Fab′ fragments joined by the heavy chain hinge region). Recombinant methods have been used to generate even smaller antigen-binding fragments, referred to as “single chain Fv” (variable fragment) or “scFv,” consisting of VL and VH joined by a synthetic peptide linker.
- Single Domain Antibodies
- While the antigen binding unit of a naturally-occurring antibody (e.g., in humans and most other mammals) is generally known to be comprised of a pair of V regions (VL/VH), camelid species express a large proportion of fully functional, highly specific antibodies that are devoid of light chain sequences. The camelid heavy chain antibodies are found as homodimers of a single heavy chain, dimerized via their constant regions. The variable domains of these camelid heavy chain antibodies are referred to as VHH domains and retain the ability, when isolated as fragments of the VH chain, to bind antigen with high specificity (Hamers-Casterman et al., 1993, Nature 363: 446-448; Gahroudi et al., 1997, FEBS Lett. 414: 521 -526). Antigen binding single VH domains have also been identified from, for example, a library of murine VH genes amplified from genomic DNA from the spleens of immunized mice and expressed in E. coli (Ward et al, 1989, Nature 341: 544-546). Ward et al. named the isolated single VH domains “dAbs,” for “domain antibodies”. The term “dAb” will refer herein to a single immunoglobulin variable domain (VH, VHH or VL) polypeptide that specifically binds antigen. A “dAb” binds antigen independently of other V domains; however, as the term is used herein, a “dAb” can be present in a homo- or heteromultimer with other VH or VL domains where the other domains are not required for antigen binding by the dAb, i.e., where the dAb binds antigen independently of the additional VH, VHH or VL domains. Single immunoglobulin variable domains, for example, VHH, are the smallest antigen-binding antibody unit known. For use in therapy, human antibodies are preferred, primarily because they are not as likely to provoke an immune response when administered to a patient. Isolated non-camelid VH domains tend to be relatively insoluble and are often poorly expressed. Comparisons of camelid VHH with the VH domains of human antibodies reveals several key differences in the framework regions of the camelid VHH domain corresponding to the VR/VL interface of the human VH domains. Mutation of these residues of human VH3 to more closely resemble the VHH sequence (specifically
Gly 44 Glu,Leu 45 Arg andTrp 47 Gly) has been performed to produce “camelized” human VH domains (Davies & Riechmann, 1994, FEBS Lett. 339: 285-290) in an attempt to yield improved expression and solubility. Variable domain amino acid numbering used herein is consistent with the Kabat numbering convention (Kabat et al., 1991, Sequences of Immunological Merest, 5th ed. U.S. Dept. Health & Human Services, Washington, D.C.). - WO 03/035694 (Muyldermans) reports that a Trp 103 Arg mutation improves the solubility of non-camelid VH domains, Davies & Riechmann, (1995, Biotechnology N.Y. 13: 475-479) also report production of a phage-displayed repertoire of camelized human VH domains and selection of clones that bind hapten with affinities in the range of 100-400 nM, but clones selected for binding to protein antigen had weaker affinities. The antigen binding domain of an antibody comprises two separate regions: a heavy chain variable domain (VH) and a light chain variable domain (VL: which can be either Vκ or Vλ). The antigen binding site itself is formed by six polypeptide loops: three from VH domain (H1, H2 and H3) and three from VL domain (L1, L2 and L3). A diverse primary repertoire of V genes that encode the VH and VL domains is produced by the combinatorial rearrangement of gene segments. The VH gene is produced by the recombination of three gene segments, VH, D and JH. In humans, there are approximately 51 functional VH segments (Cook and Tomlinson, 1995, Immunol. Today, 16: 237), 25 functional D segments (Corbett et al., 1997 J. Mol. Biol., 268: 69) and 6 functional JH segments (Ravetch et al., 1981, Cell, 27: 583-591), depending on the haplotype. The VH segment encodes the region of the polypeptide chain which forms the first and second antigen binding loops of the VH domain (H1 and H2), whilst the VH, D and JH segments combine to form the third antigen binding loop of the VH domain (H3). The VL gene is produced by the recombination of only two gene segments, VL and JL. In humans, there are approximately 40 functional Vκ segments (Schable and Zachau (1993) Biol. Chem. Hoppe Scyler, 374: 1001-1022), 31 functional Vλ segments (Williams et al., 1996, J. Mol. Biol., 264: 220-232; Kawasaki et al., 1997, Genome Res., 7: 250-261), 5 functional Jκ segments (Hieter et al., 1982, J. Biol. Chef., 257: 1516-1522) and 4 functional Jλ segments (Vasicek and Leder, 1990, J. Exp. Med., 172: 609-620), depending on the haplotype. The VL segment encodes the region of the polypeptide chain which forms the first and second antigen binding loops of the VL domain (L1 and L2), whilst the VL and JL segments combine to form the third antigen binding loop of the VL domain (L3).
- Antibodies selected from this primary repertoire are believed to be sufficiently diverse to bind almost all antigens with at least moderate affinity. High affinity antibodies are produced by “affinity maturation” of the rearranged genes, in which point mutations are generated and selected by the immune system on the basis of improved binding. Analysis of the structures and sequences of antibodies has shown that five of the six antigen binding loops (H1, H2, L1, L2, L3) possess a limited number of main-chain conformations or canonical structures (Chothia and Lesk, 1987, Mol. Biol., 196; 901-917; Chothia al., 1989, Nature, 342: 877-883). The main-chain conformations are determined by (i) the length of the antigen binding loop, and (ii) particular residues, or types of residue, at certain key position in the antigen binding loop and the antibody framework. Analysis of the loop lengths and key residues has enabled us to predict the main-chain conformations of H1, H2, L1, L2 and L3 encoded by the majority of human antibody sequences (Chothia et al., 1992, J. Mol. Biol., 227: 799-817; Tomlinson et al., 1995, EMBO J., 14; 4628-4638; Williams et al., 1996, J. Mol. Biol., 264: 220-232). Although the H3 region is much more diverse in terms of sequence, length and structure (due to the use of D segments), it also forms a limited number of main-chain conformations for short loop lengths which depend on the length and the presence of particular residues, or types of residue, at key positions in the loop and the antibody framework (Martin et al., 1996, J. Mol. Biol, 263: 800-815; Shirai et al., 1996, FEBS Letters, 399: 1-8).
- Bispecific antibodies comprising complementary pairs of VH and VL regions are known in the art. These bispecific antibodies must comprise two pairs of VH and VLs, each VH/VL pair binding to a single antigen or epitope. Methods described involve hybrid hybridomas (Milstein & Cuello, Nature, 1983, 305:537-40), minibodies (Hu et al., 1996,
Cancer Res 30 56:3055-3061), diabodies (Holliger et al., 1993, Proc. Natl.Acad. Sci. USA 90, 6444-6448; WO 94/13804), chelating recombinant antibodies (CRAbs; Neri et al., 1995, J. Mol. Biol. 246, 367-373), biscFv (e.g. Atwell et al., 1996, Mol. Immunol. 33, 1301-1312), “knobs in holes” stabilized antibodies (Carter et al., 1997, Protein Sci. 6, 781-788). In each case, each antibody species comprises two antigen-binding sites, each fashioned by a complementary pair of VH and VL domains. Each antibody is thereby able to bind to two different antigens or epitopes at the same time, with the binding to EACH antigen or epitope mediated by a VH and its complementary VL domain. Each of these techniques presents its particular disadvantages; for instance in the case of hybrid hybridomas, inactive VH/VL pairs can greatly reduce the fraction of bispecific IgG. Furthermore, most bispecific approaches rely on the association of the different VH/VL pairs or the association of VH and VL chains to recreate the two different VH/VL binding sites. It is therefore impossible to control the ratio of binding sites to each antigen or epitope in the assembled molecule and thus many of the assembled molecules will bind to one antigen or epitope but not the other. In some cases it has been possible to engineer the heavy or light chains at the sub-unit interfaces (Carter et al., 1997) in order to improve the number of molecules which have binding sites to both antigens or epitopes, but this never results in all molecules having binding to both antigens or epitopes. There is some evidence that two different antibody binding specificities might be incorporated into the same binding site, but these generally represent two or more specificities that correspond to structurally related antigens or epitopes or to antibodies that are broadly cross-reactive. For example, cross-reactive antibodies have been so described, usually where the two antigens are related in sequence and structure, such as hen egg white lysozyme and turkey lysozyme (McCafferty et al., WO 92/01047) or to free hapten and to hapten conjugated to carrier (Griffiths et al., 1994, EMBO J 13:14 3245-60). In a further example, WO 02/02773 (Abbott Laboratories) describes antibody molecules with “dual specificity”. The antibody molecules referred to are antibodies raised or selected against multiple antigens, such that their specificity spans more than a single antigen. Each complementary VH/VL pair in the antibodies of WO 02/02773 specifies a single binding specificity for two or more structurally related antigens; the VH and VL domains in such complementary pairs do not each possess a separate specificity. The antibodies thus have a broad single specificity which encompasses two antigens, which are structurally related. Furthermore natural autoantibodies have been described that are polyreactive (Casali & Nolkins, 1989, Ann. Rev. Immunol. 7, 515-531), reacting with at least two (usually more) different antigens or epitopes mat are not structurally related. It has also been shown that selections of random peptide repertoires using phage display technology on a monoclonal antibody will identify a range of peptide sequences that fit the antigen binding site. Some of the sequences are highly related, fitting a consensus sequence, whereas others are very different and have been termed mimotopes (Lane & Stephen, 1993, Current Opinion in Immunology, 5,268-271). It is therefore clear that a natural four-chain antibody, comprising associated and complementary VH and VL domains, has the potential to bind to many different antigens from a large universe of known antigens. It is less clear how to create a binding site to two given antigens in the same antibody, particularly those which are not necessarily structurally related. Protein engineering methods have been suggested that may have a bearing on this. For example, it has also been proposed that a catalytic antibody could be created with a binding activity to a metal ion through one variable domain, and to a hapten (substrate) through contacts with the metal ion and a complementary variable domain (Barbae et al, 1993, Proc. Natl.Acad. Sci USA 90,6385-6389). However in this case, the binding and catalysis of the substrate (first antigen) is proposed to require the binding of the metal ion (second antigen). Thus the binding to the VH/VL pairing relates to a single but multi component antigen. Methods have been described for the creation of bispecific antibodies from camel antibody heavy chain single domains in which binding contacts for one antigen are created in one variable domain, and for a second antigen in a second variable domain. However the variable domains were not complementary. Thus a first heavy chain variable domain is selected against a first antigen, and a second heavy chain variable domain against a second antigen, and then both domains are linked together on the same chain to give a bispecific antibody fragment (Conrath et al, J. Biol. Chem. 270, 27589-27594). However the camel heavy chain single domains are unusual in that they are derived from natural camel antibodies which have no light chains, and indeed the heavy chain single domains are unable to associate with camel light chains to form complementary VH and VL pairs. Single heavy chain variable domains have also been described, derived from natural antibodies which are normally associated with light chains (from monoclonal antibodies or from repertoires of domains; see EP-A-0368684). These heavy chain variable domains have been shown to interact specifically with one or more related antigens but have not been combined with other heavy or light chain variable domains to create a ligand with specificity for two or more different antigens. Furthermore, these single domains have been shown to have a very short in viva half-life. Therefore, such domains are of limited therapeutic value. It has been suggested to make bispecific antibody fragments by linking heavy chain variable domains of different specificity together (as described above). The disadvantage with this approach is that isolated antibody variable domains may have a hydrophobic interface that normally makes interactions with the light chain and is exposed to solvent and may be “sticky” allowing the single domain to bind to hydrophobic surfaces. Furthermore, in the absence of a partner light chain, the combination of two or more different heavy chain variable domains and their association, possibly via their hydrophobic interfaces, may prevent them from binding to one or both of the ligands they are able to bind in isolation. Moreover, in this case the heavy chain variable domains would not be associated with complementary light chain variable domains and thus may be less stable and readily unfold (Worn & Pluckthun, 1998, Biochemistry 37:13120-7). - Human/mouse chimeric antibodies have been created in which antibody variable region sequences from the mouse genome are combined with antibody constant region sequences from the human genome. The chimeric antibodies exhibit the binding characteristics of the parental mouse antibody, and the effector functions associated with the human constant region. The antibodies are produced by expression in a host cell, including for example Chinese Hamster Ovary (CHO). NS0 myeloma cells, COS cells and SP2 cells.
- Such chimeric antibodies have been used inhuman therapy, however antibodies to these chimeric antibodies have been produced by the human recipient. Such anti-chimeric antibodies are detrimental to continued therapy with chimeric antibodies.
- It has been suggested that human monoclonal antibodies are expected to be an improvement over mouse monoclonal antibodies for in vivo human therapy. From work done with antibodies from Old World primates (rhesus monkeys and chimpanzees) it has been postulated mat these non-human primate antibodies will be tolerated in humans because they are structurally similar to human antibodies (Ehrlich PH et al., 1988, Human and primate monoclonal antibodies for in vivo therapy. Clin Chem. 34:9 pg 1681-1688). Furthermore, because human antibodies are non-immunogenic in Rhesus monkeys (Ehrlich et al., 1987, Hybridoma; 6:151-60), it is likely that the converse is also applicable and primate antibodies will be non-immunogenic in humans. These monoclonal antibodies are secreted by hybridomas constructed by fusing lymphocytes to a human x mouse heteromyeloma.
-
EP 0 605 442 discloses chimeric antibodies which bind human antigens. These antibodies comprise the whole variable region from an Old World monkey and the constant region of a human or chimpanzee antibody. One of the advantages suggested in this reference for these constructs is the ability to raise antibodies in Old World monkeys to human antigens which are less immunogenic in humans compared with antibodies raised in a mouse host. - New World primates (infraorder—Platyrrhini) comprise at least 53 species commonly divided into two families, the Callithricidae and Cebidae. The Callithricidae consist of marmosets and tamarins. The Cebidae includes the squirrel monkey, titi monkey, spider monkey, woolly monkey, capuchin, uakaris, sakis, night or owl monkey and the howler monkey.
- Evolutionarily distant primates, such as New World primates, are not only sufficiently different from humans to allow antibodies against human antigens to be generated, but are sufficiently similar lo humans to have antibodies similar to human antibodies so that the host does not generate an anti-antibody immune response when such primate-derived antibodies are introduced into a human.
- Previous studies have characterised the expressed immunoglobulin heavy chain repertoire of the Callithrix jacchus marmoset (von Budingen et al., 2001, Immunogenetics; 53:557-563). Six IGHV subgroups were identified which showed a high degree of sequence similarity to their human IGHV counterparts. The framework regions were more conserved when compared to the complementarity determining regions (CDRs). The degree of similarity between C. jacchus and human 1GHV sequences was less than between non-human Old World primates and humans.
- In a first aspect the present invention provides a chimeric antibody polypeptide comprising an antigen binding site, wherein the antigen binding site comprises a human variable domain having at least one New World Primate CDR.
- In a second aspect the present invention provides a method of producing an antibody polypeptide according to the first aspect of the invention, the method comprising the steps of:
-
- (i) providing an acceptor sequence encoding a human variable domain; and
- (ii) replacing a CDR sequence of the variable domain with a donor CDR sequence, wherein the donor sequence is a New World Primate CDR sequence.
- In a third aspect the present invention provides a chimeric domain antibody (dAb) which binds human TNF-α, the dAb comprising an immunoglobulin heavy or light chain variable domain, wherein said variable domain comprises at least one New World Primate CDR.
- In a fourth aspect the present invention provides a pharmaceutical composition comprising an effective amount of an antibody polypeptide according to the first or third aspects of the invention, together with a pharmaceutically acceptable carrier or diluent.
-
FIG. 1 shows the amino acid (SEQ ID No:6) and nucleotide sequence (SEQ ID No:5) of the acceptor dAb. -
FIG. 2 shows the nucleotide and amino acid sequences of eleven (11) marmoset and six. (6) Owl monkey Vκ gene segments. -
FIG. 3 shows the acceptor dAb amino acid and nucleotide sequence (both strands). The restriction digest sites for Kpn I and San DI which excises a region including the CDR2 is indicated in the figure. CDR2 residues removed are indicated in underline. -
FIG. 4 shows sequence alignments showing oligonucleotides used during cloning and final sequence confirmation of the nucleotide (A) and amino acid (B) sequences shown inFIG. 2 . -
FIG. 5 demonstrates the ability of CDR2-grafted dAbs to inhibit the binding of TNF to recombinant TNF receptor. The dAbs tested were as follows: Owl Monkey 1 (CDR=YAATKLQS; SEQ ID No:1), Owl Monkey 2 (CDR=YEASSLQS; SEQ ID No:2), Marmoset 1 (CDR=YEASKLQS; SEQ ID No:3), Marmoset 2 (CDR=YSASNLET; SEQ ID No:4) and Acceptor dAb (CDR=YSASELQS; SEQ ID No:49). -
FIG. 6 demonstrates the improved ability ofCompounds 100 and 123 to neutralise the cytotoxic activity of TNF on mouse L929 fibroblasts relative toCompound 145. - In a first aspect the present invention provides a chimeric antibody polypeptide comprising an antigen binding site, wherein the antigen binding site comprises a human variable domain having at least one New World Primate CDR.
- In a third aspect the present invention provides a chimeric domain antibody (dAb) which binds human TNF-α, the dAb comprising an immunoglobulin heavy or light chain variable domain, wherein said variable domain comprises at least one New World Primate CDR.
- In a fourth aspect the present invention provides a pharmaceutical composition comprising an effective amount of an antibody polypeptide according to the first or third aspects of the invention, together with a pharmaceutically acceptable carrier or diluent.
- In an embodiment of the present invention the human variable domain comprises at least one human framework region having an amino acid sequence encoded by a human germline antibody gene segment, or an amino acid sequence comprising up to 5 amino acid differences relative to the amino acid sequence encoded by the human germline antibody gene segment.
- The human variable domain preferably comprises four human framework regions, FR1, FR2, FR3 and FR4 having amino acid sequences encoded by a human germline antibody gene segment, or the amino acid sequences which collectively contain up to 10 ammo acid differences relative to the amino acid sequences encoded by said human germline antibody gene segment.
- Preferably the human germline antibody gene segment selected from the group consisting of DP47, DP45, DP48 and DPK9.
- The New World Primate CDR may be any CDR, however, it is preferred that the New World Primate CDR is CDR2.
- Alternatively the New World Primate CDR is CDR1 or CDR3.
- It is also preferred that the New World Primate CDR sequence is a germline New World Primate CDR sequence.
- The antibody polypeptide of the present invention is preferably selected from a dAb, scFv, Fab, (Fab′)2, Fv, disulphide bonded Fv, IgG, and a diabody.
- The antibody polypeptide of the present invention is preferably directed against TNF-α.
- In another preferred embodiment the human variable domain amino acid sequence comprises a Kpn1 restriction site spaced from a SanD1 restriction site, said CDR of the human variable domain being between the restriction sites.
- It is also preferred that the New World Primate CDR sequence is obtainable from New World Primate DNA by PCR using primer pair VK1BL (SEQ ID No:11)/VK1BL35a (SEQ ID No:12) or primer pair VK1BL (SEQ ID No:11/VK1BL35b (SEQ ID No:13).
- The present invention also provides a chimeric domain antibody (dAb) which binds to human TNF-α, wherein the dAb is a human dAb that binds human TNF-α in which at least one of the CDRs is replaced with the corresponding CDR from a New World Primate.
- The present invention also provides a method of producing an antibody polypeptide according to the first aspect of the invention, the method comprising the steps of:
-
- (i) providing an acceptor sequence encoding a human variable domain; and
- (ii) replacing a CDR sequence of the variable domain with a donor CDR sequence, wherein the donor sequence is a New World Primate CDR sequence.
- It is preferred that in step (ii) said CDR of said human variable domain is replaced by said donor New World Primate CDR using restriction digestion and annealing of an oligonucleotide encoding the donor CDR into the acceptor sequence.
- It is preferred that the method further comprises affinity maturing the variable domain produced in step (ii).
- As used herein the term “New World Primate CDR” refers to a CDR sequence obtained from a New World Primate. The term encompasses modification of 1, 2 or 3 ammo acids within the sequence which may be used to achieve improved antigen binding characteristics or lower immunogenicity. The term does not, however, extend to cover modifications which result in the New World Primate CDR sequence being identical to a human CDR sequence.
- As used herein the term “human framework region” refers to a framework region obtained from a human or a human framework region having an amino acid sequence encoded by a human germline antibody gene segment, or an amino acid sequence comprising up to 5 amino acid differences relative to the amino acid sequence encoded by the human germline gene segment. The term also encompasses modification of the amino acid sequence of the framework region in order to obtain improved antigen binding characteristics or lower immunogenicity such as disclosed in U.S. Pat. No. 4,816,567, U.S. Pat. No. 5,585,089 and US 20030039649 the disclosures of which are incorporated herein by reference in their entirety. Typically where modifications are made the total number of residues changed will be 10 or less collectively over the framework regions.
- In a preferred embodiment the variable domain comprises four framework regions, wherein at least one framework region comprises an amino acid sequence derived from a corresponding framework region encoded by a human germline immunoglobulin gene.
- In a further preferred embodiment the four framework regions comprise amino acid sequences derived from corresponding framework regions encoded by human germline immunoglobulin genes.
- In yet a further preferred embodiment the human germline immunoglobulin gene is selected from the group consisting of DP47, DP45, DP48 and DPK9.
- The term “domain” as used herein is meant a folded protein structure which retains its tertiary structure independently of the rest of the protein. Generally, domains are responsible for discrete functional properties of proteins, and in many cases may be added, removed or transferred to other proteins without loss of function of the remainder of the protein and/or of the domain.
- The term immunoglobulin or antibody “variable domain” as used herein is a term of art, and includes a folded polypeptide domain comprising sequences characteristic of immunoglobulin or antibody heavy or light chain variable domains and which specifically binds an antigen.
- The term “immunoglobulin” as used herein refers to a family of polypeptides which retain the immunoglobulin fold characteristic of antibody molecules, which contains two β sheets and, usually, a conserved disulphide bond. Members of the immunoglobulin superfamily are involved in many aspects of cellular and non-cellular interactions in vivo, including widespread roles in the immune system (for example, antibodies, T-cell receptor molecules and the like), involvement in cell adhesion (for example the ICAM molecules) and intracellular signalling (for example, receptor molecules, such as the PDGF receptor). The present invention is applicable to all immunoglobulin superfamily molecules which possess binding domains. Preferably, the present invention relates to antibody polypeptides.
- New World primates (infraorder—Platyrrhini) comprise at least 53 species commonly divided into two families, the Callithricidae and Cebidae. The Callithricidae consist of marmosets and tamarins. The Cebidae includes the squirrel monkey, titi monkey, spider monkey, woolly monkey, capuchin, uakaris, sakis, night or owl monkey and the howler monkey.
- Evolutionarily distant primates, such as New World primates, are not only sufficiently different from humans to allow antibodies against human antigens to be generated, but are sufficiently similar to humans to have antibodies similar to human antibodies so that the host does not generate an anti-antibody immune response when such primate-derived antibodies are introduced into a human.
- Previous studies have characterised the expressed immunoglobulin heavy chain repertoire of the Callithrix jacchus marmoset (von Budingen H-C et al., 2001, Immunogenetics; 53:557-563). Six IGHV subgroups were identified which showed a high degree of sequence similarity to their human IGHV counterparts. The framework regions were more conserved when compared to the complementarity determining regions (CDRs). The degree of similarity between C. jacchus and human IGHV sequences was less than between non-human Old World primates and humans.
- In certain embodiments of the present invention the New World primate CDR is from the family Callithricidae.
- In yet a further embodiment of the present invention the New World primate CDR is selected from the group consisting of marmosets, tamarins, squirrel monkey, titi monkey, spider monkey, woolly monkey, capuchin, uakaris, sakis, night or owl monkey and the howler monkey. More preferably, the New World primate is a marmoset.
- In yet a further embodiment of the present invention the at least one New World primate CDR is substantially identical to a CDR encoded by a New World primate germline immunoglobulin gene.
- The term “antibody” as used herein, is intended to refer to immunoglobulin molecules comprised of two heavy chains or immunoglobulin molecules comprised of four polypeptide chains, two heavy (H) chains and two light (L) chains inter-connected by disulfide bonds. Each heavy chain is comprised of a heavy chain variable region (HCVR or VH) and a heavy chain constant region. The heavy chain constant region comprises three domains,
C H1,C H2 andC H3. Each light chain is comprised of a light chain variable region (LCVR or VL) and a light chain constant region. The light chain constant region is comprised of one domain, CL. The VH and VL regions can be further subdivided into regions of hypervariability, termed complementarity determining regions (CDR), interspersed with regions that are more conserved, termed framework regions (PR). Each VH and VL is composed of three CDRs and four FRs, arranged from amino-terminus to carboxy-terminus in the following order: FR1, CDR1, FR2, CDR2, FR3, CDR3, FR4. - The term “antibody polypeptide” as used herein refers to a polypeptide comprising one or more components or derivatives of an immunoglobulin that exhibit the ability to bind to an antigen. It has been shown that the antigen-binding function of an antibody can be performed by fragments of a full length antibody. Examples of binding fragments encompassed within the term “antibody polypeptide” include (i) a Fab fragment, a monovalent fragment consisting of the VL, VH, CL and
C H1 domains; (ii) a F(ab′)2 fragment, a bivalent fragment comprising two Fab fragments linked by a disulfide bridge at the hinge region; (iii) a Fd fragment consisting of the VH andC H1 domains; (iv) a Fv fragment consisting of the VL and VH domains of a single arm of an antibody, (v) a dAb fragment (Ward et al, 1989, Nature 341:544-546) which consists of a single VH domain, or a VL domain (van den Beucken et al, 2001, J. Mol. Biol, 310, 591-601); and (vi) an isolated complementarity determining region (CDR). Furthermore, although the two domains of the Fv fragment, VL and VH, are coded by separate genes, they can be joined, using recombinant methods, by a synthetic linker that enables them to be made as a single protein chain in which the VL and VH regions pair to form monovalent molecules (known as single chain Fv (scFv); (see eg Bird et al., 1988, Science 242:423-426 and Huston et al., 1988 Proc. Natl. Acad. Sci. USA 85:5879-5883). Such single chain Fvs are also intended to be encompassed within the term “antigen-binding portion” of an antibody. Other forms of single chain Fvs and related molecules such as diabodies or triabodies are also encompassed. Diabodies are bivalent antibodies in which VH and VL domains are expressed on a single polypeptide chain, but using a linker that is too short to allow for pairing between the two domains on the same chain, thereby forcing the domains to pair with complementary domains of another chain and creating two antigen binding sites (see e.g., Holliger, et al., 1993, Proc. Natl. Acad. Sci. USA, 90:6444-6448; Poljak, et al., 1994, Structure, 2:1121-1123). - Thus in certain embodiments of the present invention the antibody polypeptide is selected from the group consisting of a dAb, scFv, Fab, F(ab′)2, Fv, disulphide bonded Fv, a diabody and IgG.
- Preferably, the antibody polypeptide further comprises a human or non-human primate constant region sequence. Examples of non-human primates include, but are not limited to, chimpanzees, oranguatangs and baboons.
- The constant region sequence (Fc portion) is preferably obtained from a human or non-human primate immunoglobulin sequence. The primate sequence may be a New World primate or an Old World primate sequence. Suitable Old World primates include chimpanzee, or other hominid ape eg. gorilla or orangutan, which because of their close phylogenetic proximity to humans, share a high degree of homology with the human constant region sequence. Sequences which encode for human or primate constant regions are available from databases including e.g. The National Centre for Biotechnology Information protein and nucleotide databases, The Kabat Database of Sequences of Proteins of Immunological Interest.
- In a preferred embodiment of the present invention the antibody polypeptide is a domain antibody (dAb).
- Domain antibodies (dAb) are small functioning binding units of antibodies and correspond to the variable regions of either the heavy (VH) or light (VL) chains of antibodies. Domain antibodies have a molecular weight of approximately 13 kDa, or less than one tenth the size of a full antibody.
- Antibody light chains are referred to as either kappa or lambda light chains and the heavy chains as gamma, mu, delta, alpha or epsilon. The variable region gives the antibody its specificity. Within each variable region are regions of hypervariability, otherwise known as complementarity determining regions (CDRs) which are flanked by more conserved regions referred to as framework regions. Within each variable region are three CDRs and four framework regions.
- In contrast to conventional antibodies, domain antibodies are well expressed in bacterial, yeast and mammalian systems. Their small size allows for higher molar quantities per gram or product, thus providing a significant increase in potency per dose. In addition, domain antibodies can be used as a building block to create therapeutic products such as multiple targeting dAbs in which a construct containing two or more variable domains bind to two or more therapeutic targets, or dAbs targeted for pulmonary or oral administration.
- An increase in binding is demonstrated by a decrease in KD (koff/kon) for the antibody or antigen binding portion thereof. An increase in potency is demonstrated in biological assays. For example, assays that can be used to measure the potency of the antibody or antigen-binding portion thereof include the TNFα-induced L929 cytotoxicity neutralisation assay, IL-12-induced human PHA-activated peripheral blood mononuclear cell (PBMC) proliferation assay, and RANKL mediated osteoclast differentiation of mouse splenocytes (Stem, 1990, Proc. Natl. Acad. Sci. USA 87:6808-6812; Kong, et al., 1990, Nature 397:315-323; Matthews and Neale in Lymphokines and Interferons, a Practical Approach, 1987, M. J. Clemens, A. G. Morris and A. J. H. Gearing, eds., IRL Press, p. 221).
- The CDR sequences may be obtained from several sources, for example, databases e.g. The National Centre for Biotechnology Information protein and nucleotide databases www.ncbi.nlm.nih.gov, The Kabat Database of Sequences of Proteins of Immunological Interest www.kabatdatabase.com, or the IMGT database www.imgt.cines.fr. Alternatively, the CDR regions can be predicted from the VH and VL domain repertoire (see for example Kabat and Wu, 1971, Ann. NY Acad. Sci. 190:382-393). The CDR sequence may be a genomic DNA or a cDNA.
- There are a number of ways in which a replacement CDR may be grafted into a variable domain sequence and such methods will be familiar to those skilled in the art. The preferred method of the present invention involves replacement of the CDR2 in the variable region domain via primer directed mutagenesis. This method consists of annealing a synthetic oligonucleotide encoding a desired mutations to a target region where it serves as a primer for initiation of DNA synthesis in vitro, extending the oligonucleotide by a DNA polymerase to generate a double-stranded DNA that carries the desired mutations, and ligating and cloning the sequence into an appropriate expression vector.
- In one embodiment of the invention, the variable domain sequence into which the CDR is grafted is the “dAb acceptor sequence” (designated Compound 128; SEQ ID No:6) provided in
FIG. 1 . - As used herein the term “chimeric” is meant that the antibody polypeptide or domain antibody includes sequences from more than one species.
- The anti-human TNF-α dAb according to the invention can be used to detect human TNF-α for example in a biological sample, such as serum or plasma using a conventional immunoassay, such as an enzyme linked immunosorbent assay (ELISA), a radioimmunoassay (RIA) or tissue immunohistochemistry. The anti-human TNF-α dAb according to the invention can be assayed in biological fluids by a competition immunoassay using recombinant human TNF-α standards label led with a detectable substance and an unlabelled anti-human TNF-α antibody.
- The anti-human TNF-α dAb according to the invention may also be used to detect TNF-α from species other than humans eg. chimpanzee, marmoset, rhesus, mouse, pig.
- The anti-human TNF-α dAb according to the invention may also be used in cell culture applications where it is desired to inhibit TNF-α activity.
- The invention also provides a method for treating a disorder characterised by human TNF-α activity in a human subject, comprising administering to the subject a pharmaceutical composition according to the second aspect of the invention.
- A disorder characterised by human TNF-α activity is intended to include diseases and other disorders in which the presence of TNF-α in a subject suffering from the disorder has been shown to be or is suspected of being either responsible for the pathophysiology of the disorder or a factor which contributes to a worsening of the disorder. Preferably, the disorder characterised by human TNF-α activity is selected from the group consisting of inflammation, inflammatory diseases, sepsis, including septic shock, endotoxic shock, gram negative sepsis and toxic shock syndrome; autoimmune disease, including rheumatoid arthritis, rheumatoid spondylitis, osteoarthritis and gouty arthritis, allergy, multiple sclerosis, autoimmune diabetes, autoimmune uveitis and nephrotic syndrome; infectious disease, including fever and myalgias due to infection and cachexia secondary to infection; graft versus host disease; tumour growth or metastasis; pulmonary disorders including adult respiratory distress syndrome, shock lung, chronic pulmonary inflammatory disease, pulmonary sarcoidosis, pulmonary fibrosis and silicosis; inflammatory bowel disorders including Crohn's disease and ulcerative colitis; cardiac disorders; inflammatory bone disorders, hepatitis, coagulation disturbances, burns, reperfusion injury, keloid formation and scar tissue formation.
- In a fourth aspect, the invention provides a pharmaceutical composition comprising an effective amount of the antibody polypeptide according to the first aspect of the invention or a chimeric domain antibody according to the third aspect of the invention, together with a pharmaceutically acceptable carrier or diluent.
- A “pharmaceutically acceptable carrier” includes any and all solvents, dispersion media, coatings, antibacterial and antifungal-agents, isotonic and absorption delaying agents, and the like which are physiologically compatible. Examples of pharmaceutically acceptable carriers include one or more of water, saline, phosphate buffered saline, dextrose, glycerol, ethanol, and the like as well as combinations thereof. In many cases it will be preferable to include isotonic agents, for example, sugars, polyalcohols such as mannitol, sorbitol, or sodium chloride in the composition. Pharmaceutically acceptable substances such as welling or minor amounts of auxiliary substances such as wetting or emulsifying agents, preservatives or buffers.
- The composition may be in a variety of forms, including liquid, semi-solid and solid dosage forms, such as liquid solutions (eg injectable and infusible solutions), dispersions or suspensions, tablets, pills, powders, liposomes and suppositories. Preferably, the composition is in the form of an injectable solution for immunization. The administration may be intravenous, subcutaneous, intraperitoneal, intramuscular, transdermal, intrathecal, and intra-arterial.
- Therapeutic compositions typically must be sterile and stable under the conditions of manufacture and storage. The compositions can be formulated as a solution, microemulsion, dispersion, liposome, or other ordered structure suitable to high drug concentration. Sterile injectable solutions can be prepared by incorporating the active compound (i.e. antibody polypeptide) into the required amount in an appropriate solvent with one or a combination of ingredients listed above, followed by filtered sterilisation.
- The composition may also be formulated as a sterile powder for the preparation of sterile injectable solutions. The proper fluidity of a solution can be maintained by for example, use of a coating such as lecithin and/or surfactants.
- In certain embodiments, the active compound may be prepared with a carrier that will protect the compound against rapid release, such as a controlled release formulation, including implants, transdermal patches, and microencapsulated delivery systems.
- Compatible polymers may be used such as ethylene vinyl acetate, polyanhydrides, polyglycolic acid, collagen, polyorthoesters and polylactic acid.
- The composition may also be formulated for oral administration. In this embodiment, the antibody polypeptide may be enclosed in a hard or soft shell gelatin capsule, compressed into tablets, or incorporated directly into the subject's diet.
- The composition may also be formulated for rectal administration.
- Supplementary active compounds can also be incorporated into the composition. The antibody polypeptide may be co-formulated with and/or co-administered with one or more additional therapeutic agents eg. anti-inflammatory compounds, soluble TNF-α receptor or a chemical agent that inhibits human TNF-α production, or antibodies that bind other targets such as cytokines or cell surface molecules. Alternatively, it may be co-administered with a soluble immunochemical reagent such as protein A, C, G or L.
- An effective amount may include a therapeutically effective amount or prophylactically effective amount of the antibody polypeptide of the invention. A therapeutically effective amount refers to an amount effective at dosages and for periods of time necessary, to achieve the desired therapeutic result. A prophylactically effective amount refers to an amount effective, at dosages and for periods of lime necessary, to achieve the desired prophylactic result.
- In a preferred embodiment the composition is administered to mammals, preferably humans or primates.
- In order that the nature of the present invention may be more clearly understood, preferred forms thereof will now be described with reference to the following non-limiting examples.
- Materials and Methods
- Isolation of New World Primate VL Genes
- Marmoset (genus Callidirix, species unknown) and Owl monkey (Aotus trivirgatus) genomic DNA were obtained from the European Collection of Cell Cultures (ECACC), catalogue numbers 85011419 and 90110510 respectively. Marmoset DNA was derived from cell line B95-8 while Owl monkey DNA came from cell line OMK 637-69.
- Degenerate primers based on human Vκ leader sequences and recombination signal sequences (RSS) were derived from Walter and Tomlinson, Antibody Engineering: A Practical Approach (1996). The primers used for amplification of germline Vκ DNA were as follows:
-
Primer VK1BL AATCKCAGGTKCCAGATG (SEQ ID No: 11) Primer VK1BL35a GTTYRGGTKKGTAACACT (SEQ ID No: 12) Primer VK1BL35b ATGMCTTGTWACACTGTG (SEQ ID No: 13) - Genomic PCR (30 cycles) was performed using Taq polymerase with either primer pair VK1BLxVK1BL35a or VK1LxVK1BL35b. There was overlap between the sequences cloned and the two primer sets used.
- PCR products were cloned into Invitrogen's TOPO TA cloning kit (Cat No K4500-01) and sequenced with M13 forward and pUC reverse primers. Sequence was confirmed in forward and reverse directions. In order to further confirm key sequences were not subject, to PCR errors, the PCR and cloning process was repeated twice for marmoset sequences. Nucleotide (SEQ ID Nos:14-24 and SEQ ID Nos:36-41) and amino acid (SEQ ID Nos:25-35 and SEQ ID Nos:42-47) sequences are given in
FIG. 2 .Marmoset sequences Sequences Sequences - Oligo Synthesis and Cloning into Acceptor Sequence
- Four CDR sequences, namely YAATKLQS (SEQ ID No:1) from Owl monkey sequence 1 (SEQ ID No:42), YEASSLQS (SEQ ID No:2) from Owl monkey sequence 2 (SEQ ID No:43), YEASKLQS (SEQ ID No:3) from Marmoset sequence 1 (SEQ ID No:25), and YSASNLET (SEQ ID No:4) from Marmoset sequence 2 (SEQ ID No:26), were chosen from the amino acid sequences shown in
FIG. 2 as indicated.Owl Monkey sequence 5, YYASSLQS (SEQ ID No:48) was found to be identical to GI6176295 an Aotus nancymaae (Ma's night monkey) cDNA sequence, all other sequences were unique. - An acceptor variable region (anti-TNF domain antibody) sequence in the expression vector (Domantis proprietary vector) was digested (25 μg) sequentially with KpnI and SanDI which excises the majority of FR2 as well as CDR2 as indicated on the restriction digest map. The vector was then gel purified to remove the excised wild-type FR2 and CDR2 sequence.
- Oligo annealing was performed by incubating oligo pairs (500 pmol of each as shown in
FIGS. 4A and 4B ) at 95° C. for 5 minutes followed by 65° C. for 5 minutes and then allowed to reach room temperature slowly on a hot block. Overlaps were then filled in during a Klenow reaction in the presence of dNTPs. - Affinity Maturation
- The marmoset CDR-grafted dAb Compound 145 (SEQ ID No:7) was affinity matured by constructing 14 separate libraries, each a diversification of the sequence of SEQ ID No:7 at a single amino acid residue. The selected residues are shown shaded below.
- The selection was based upon residues in CDR1 and CDR3 that are known to be diversified in the mature human Ig repertoire, and framework residues that have been observed to produce functional proteins after mutagenesis in related dAbs. For each of the selected residues, complimentary forward and reverse PCR primer pairs were designed with NKK degeneracy, and two initial PCR reactions were performed each with a single mutagenic primer and flanking primer. After clean-up, the two PCR products were annealed and then amplified using flanking primers alone (splicing by overlap extension of PCR; Lowman H. L. & Clackson T. (eds), Phage Display: A practical approach, Oxford University Press , Oxford, UK). Clones were initially screened by ELISA using solid-phase TNF, and positive clones were sequenced. dAb protein was purified from the best clones and evaluated for potency in receptor binding assays and L929 cytotoxicity assays. Compounds 100 (SEQ ID No:9) and 123 (SEQ ID No:8) were found to have improved TNF-neutralization relative to the parent dAb, Compound 145 (SEQ ID No:7).
- Combination of the affinity-enhancing substitutions of Compounds 100 (SEQ ID No:9) and 123 (SEQ ID No:8), yielded an anti-TNF dAb with further improved potency in the L929 cytotoxicity assay (Compound 196; SEQ ID No:10).
- Results
- Potency of Anti-TNF dAb Clones in Receptor Binding Assay (RBA) and Cytotoxocity Assay
- The ability of the anti-TNF dAbs to inhibit TNF binding to its receptor and to neutralize TNF-mediated cytotoxicity of L929 cells was conducted as follows:
- Receptor Binding Assay
- dAbs diversified in the 14 selected positions were tested for the ability to inhibit the binding of TNF to recombinant TNF receptor 1 (p55). Briefly, Maxisorp plates were incubated overnight with 30 mg/ml anti-human Fc mouse monoclonal antibody (Zymed, San Francisco, USA). The wells were washed with phosphate buffered saline (PBS) containing 0.05% Tween-20 and then blocked with 1% BSA in PBS before being incubated with 100 ng/
ml TNF receptor 1 Fc fusion protein (R&D Systems, Minneapolis, USA). Each dAb was mixed with TNF which was added to the washed wells at a final concentration of 10 ng/ml. TNF binding was detected with 0.2 mg/ml biotinylated anti-TNF antibody (HyCult biotechnology, Uben, Netherlands) followed by 1 in 500 dilution of horse radish peroxidase labelled streptavidin (Amersham Biosciences, UK) and then incubation with TMB substrate (KPL, Gaithersburg, USA). The reaction was stopped by the addition of HCl and the absorbance was read at 450 nm. Anti-TNF dAb activity lead to a decrease in TNF binding and therefore a decrease in absorbance compared with the TNF only control (FIG. 5 ). - L929 Cytotoxicity Assay
- Anti-TNF dAbs identified by the minilibrary diversification approach, including Compounds 100 (SEQ ID No:9) and 123 (SEQ ID No:8), were also tested for the ability to neutralise the cytotoxic activity of TNF on mouse L929 fibroblasts (Evans, T., 2000,
Molecular Biotechnology 15, 243-248). Briefly, L929 cells plated in microtitre plates were incubated overnight, with anti-TNF dAb, 100 pg/ml TNF and 1 mg/ml actinomycin D (Sigma, Poole, UK). Cell viability was measured by reading absorbance at 490 nm following an incubation with [3-(4,5-dimethylthiazol-2-yl)-5-(3-carbboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium (Promega, Madison, USA). Anti-TNF dAb activity lead to a decrease in TNF cytotoxicity and therefore an increase in absorbance compared with the TNF only control. The results, in comparison with the parent dAb Compound 145 (SEQ ID No:7) are presented inFIG. 6 . - Throughout this specification the word “comprise”, or variations such as “comprises” or “comprising”, will be understood to imply the inclusion of a stated clement, integer or step, or group of elements, integers or steps, but not the exclusion of any other element, integer or step, or group of elements, integers or steps.
- All publications mentioned in this specification are herein incorporated by reference. Any discussion of documents, acts, materials, devices, articles or the like which has been included in the present specification is solely for the purpose of providing a context for the present invention. It is not to be taken as an admission that any or all of these matters form part of the prior art base or were common general knowledge in the field relevant to the present invention as it existed in Australia or elsewhere before the priority date of each claim of this application.
- It will be appreciated by persons skilled in the art that numerous variations and/or modifications may be made to the invention as shown in the specific embodiments without departing from the spirit or scope of the invention as broadly described. The present embodiments are, therefore, lobe considered in all respects as illustrative and not restrictive.
Claims (22)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US12/158,034 US20090286962A1 (en) | 2005-12-20 | 2006-12-20 | Chimeric antibodies with part new world primate binding regions |
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2005907124 | 2005-12-20 | ||
AU2005907124A AU2005907124A0 (en) | 2005-12-20 | Anti-inflammatory dAb | |
US81727206P | 2006-06-28 | 2006-06-28 | |
PCT/AU2006/001993 WO2007070979A1 (en) | 2005-12-20 | 2006-12-20 | Chimeric antibodies with part new world primate binding regions |
US12/158,034 US20090286962A1 (en) | 2005-12-20 | 2006-12-20 | Chimeric antibodies with part new world primate binding regions |
Publications (1)
Publication Number | Publication Date |
---|---|
US20090286962A1 true US20090286962A1 (en) | 2009-11-19 |
Family
ID=38188157
Family Applications (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/659,009 Expired - Fee Related US7981414B2 (en) | 2005-12-20 | 2006-12-20 | Anti-inflammatory dAb |
US12/158,034 Abandoned US20090286962A1 (en) | 2005-12-20 | 2006-12-20 | Chimeric antibodies with part new world primate binding regions |
US13/008,342 Expired - Fee Related US8263076B2 (en) | 2005-12-20 | 2011-01-18 | Anti-inflammatory dAb |
US13/585,192 Abandoned US20130040383A1 (en) | 2005-12-20 | 2012-08-14 | Nucleic acid molecules encoding anti-inflammatory domain antibodies |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/659,009 Expired - Fee Related US7981414B2 (en) | 2005-12-20 | 2006-12-20 | Anti-inflammatory dAb |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/008,342 Expired - Fee Related US8263076B2 (en) | 2005-12-20 | 2011-01-18 | Anti-inflammatory dAb |
US13/585,192 Abandoned US20130040383A1 (en) | 2005-12-20 | 2012-08-14 | Nucleic acid molecules encoding anti-inflammatory domain antibodies |
Country Status (8)
Country | Link |
---|---|
US (4) | US7981414B2 (en) |
EP (2) | EP1969010A4 (en) |
JP (2) | JP5179374B2 (en) |
KR (1) | KR20080080651A (en) |
AU (2) | AU2006326867A1 (en) |
CA (2) | CA2634083A1 (en) |
EA (1) | EA017710B1 (en) |
WO (2) | WO2007070979A1 (en) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20070202105A1 (en) * | 2006-02-01 | 2007-08-30 | Peptech Limited | Domain antibody construct |
US20080095767A1 (en) * | 2005-08-15 | 2008-04-24 | Peptech Limited | Engineered antibodies with new world primate framework regions |
US20080255343A1 (en) * | 2006-12-08 | 2008-10-16 | Arana Therapeutics Limited | Chimeric antibodies |
US20090226428A1 (en) * | 2005-12-20 | 2009-09-10 | Arana Therapeutic Limited | Anti-inflammatory dab |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20110319597A1 (en) * | 2008-08-14 | 2011-12-29 | Caphalon Australia Pty. Ltd. | Variant domain antibodies |
CN104013724A (en) * | 2014-06-20 | 2014-09-03 | 苏州法莫生物技术有限公司 | Traditional Chinese medicine composition for improving sleep |
ES2913200T3 (en) | 2015-03-31 | 2022-06-01 | Sorriso Pharmaceuticals Inc | polypeptides |
WO2018060453A1 (en) | 2016-09-30 | 2018-04-05 | Vhsquared Limited | Compositions |
CN107469069A (en) * | 2017-08-18 | 2017-12-15 | 四川普莱美生物科技集团有限公司 | Modeling method, preparation, the preparation method of preparation, rhesus macaque pulmonary fibrosis model and its application of rhesus macaque pulmonary fibrosis model |
CN110003330B (en) * | 2019-04-12 | 2022-09-09 | 深圳普瑞金生物药业股份有限公司 | TNF-alpha single domain antibody, nucleic acid molecule and kit |
JP2022538083A (en) | 2019-06-21 | 2022-08-31 | ソリッソ ファーマシューティカルズ,インク. | Polypeptide |
AU2020294980A1 (en) | 2019-06-21 | 2022-02-17 | Sorriso Pharmaceuticals, Inc. | Polypeptides |
Citations (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5994510A (en) * | 1990-12-21 | 1999-11-30 | Celltech Therapeutics Limited | Recombinant antibodies specific for TNFα |
US20030118592A1 (en) * | 2001-01-17 | 2003-06-26 | Genecraft, Inc. | Binding domain-immunoglobulin fusion proteins |
US20030143682A1 (en) * | 2000-11-07 | 2003-07-31 | Nicolaides Nicholas C. | Antibodies and methods for generating genetically altered antibodies with high affinity |
US20030199679A1 (en) * | 1990-12-21 | 2003-10-23 | Adair John Robert | Recombinant antibodies specific for TNF-alpha |
US20040101905A1 (en) * | 2000-12-01 | 2004-05-27 | Brekke Ole Henrik Andre | Product |
US20040132101A1 (en) * | 2002-09-27 | 2004-07-08 | Xencor | Optimized Fc variants and methods for their generation |
US6821505B2 (en) * | 1997-03-03 | 2004-11-23 | Board Of Regents, The University Of Texas System | Immunoglobin-like domains with increased half lives |
US20050226863A1 (en) * | 2003-11-20 | 2005-10-13 | Massachusetts Institute Of Technology | Single-domain antibodies and uses thereof |
US20050271663A1 (en) * | 2001-06-28 | 2005-12-08 | Domantis Limited | Compositions and methods for treating inflammatory disorders |
US20060024308A1 (en) * | 2004-07-06 | 2006-02-02 | Roberto Crea | High affinity anti-TNF-alpha antibodies and method |
US20060034845A1 (en) * | 2002-11-08 | 2006-02-16 | Karen Silence | Single domain antibodies directed against tumor necrosis factor alpha and uses therefor |
US20060038027A1 (en) * | 2004-03-15 | 2006-02-23 | Boston Scientific Scimed, Inc. | Apparatus and method for fine bore orifice spray coating of medical devices and pre-filming atomization |
US20060083747A1 (en) * | 2002-12-27 | 2006-04-20 | Domantis Limited | Fc fusion |
US20070111281A1 (en) * | 2005-05-09 | 2007-05-17 | Glycart Biotechnology Ag | Antigen binding molecules having modified Fc regions and altered binding to Fc receptors |
US20070269449A1 (en) * | 2003-03-26 | 2007-11-22 | Apogenix Gmbh | Fc Fusion Proteins |
US20080071063A1 (en) * | 2006-02-03 | 2008-03-20 | Medimmune, Inc. | Protein Formulations |
US20080227958A1 (en) * | 2006-04-14 | 2008-09-18 | Trubion Pharmaceuticals Inc. | Binding proteins comprising immunoglobulin hinge and fc regions having altered fc effector functions |
US20080260738A1 (en) * | 2007-04-18 | 2008-10-23 | Moore Margaret D | Single chain fc, methods of making and methods of treatment |
US20090075338A1 (en) * | 2004-03-08 | 2009-03-19 | Zymogenetics, Inc | Dimeric fusion proteins and materials and methods for producing them |
US20090148905A1 (en) * | 2007-11-30 | 2009-06-11 | Claire Ashman | Antigen-binding constructs |
US20090226428A1 (en) * | 2005-12-20 | 2009-09-10 | Arana Therapeutic Limited | Anti-inflammatory dab |
US20090250012A1 (en) * | 2008-01-16 | 2009-10-08 | Jeffrey Hayden Greene | Automated systems for feeding animals and collecting animal excrement |
Family Cites Families (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3785186T2 (en) | 1986-09-02 | 1993-07-15 | Enzon Lab Inc | BINDING MOLECULE WITH SINGLE POLYPEPTIDE CHAIN. |
NZ243706A (en) * | 1991-07-25 | 1994-08-26 | Idec Pharma Corp | Recombinant monkey antibodies, pharmaceutical compositions |
JP4046354B2 (en) | 1996-03-18 | 2008-02-13 | ボード オブ リージェンツ,ザ ユニバーシティ オブ テキサス システム | Immunoglobulin-like domain with increased half-life |
US6225290B1 (en) * | 1996-09-19 | 2001-05-01 | The Regents Of The University Of California | Systemic gene therapy by intestinal cell transformation |
WO2000042072A2 (en) | 1999-01-15 | 2000-07-20 | Genentech, Inc. | Polypeptide variants with altered effector function |
GB0114856D0 (en) * | 2001-06-18 | 2001-08-08 | Medical Res Council | Selection by avidity capture |
US20060073141A1 (en) | 2001-06-28 | 2006-04-06 | Domantis Limited | Compositions and methods for treating inflammatory disorders |
CN1671416B (en) * | 2001-07-12 | 2013-01-02 | 杰斐逊·富特 | Super humanized antibodies |
JP2005530490A (en) * | 2002-03-29 | 2005-10-13 | シェーリング コーポレイション | Human monoclonal antibody and method for interleukin-5 and composition comprising the same |
US7696320B2 (en) | 2004-08-24 | 2010-04-13 | Domantis Limited | Ligands that have binding specificity for VEGF and/or EGFR and methods of use therefor |
US20080241166A1 (en) | 2002-06-28 | 2008-10-02 | Domantis Limited | Ligands that bind a receptor |
GB0230201D0 (en) * | 2002-12-27 | 2003-02-05 | Domantis Ltd | Retargeting |
JP2006523090A (en) | 2002-12-27 | 2006-10-12 | ドマンティス リミテッド | Bispecific single domain antibody specific for ligand and for ligand receptor |
US20090005257A1 (en) * | 2003-05-14 | 2009-01-01 | Jespers Laurent S | Process for Recovering Polypeptides that Unfold Reversibly from a Polypeptide Repertoire |
ES2609102T3 (en) | 2003-06-27 | 2017-04-18 | Bioren, LLC | Mutagenesis by review |
EP2221317A3 (en) | 2003-06-30 | 2011-07-27 | Domantis Limited | PEGylated single domain antibodies (dAb) |
EP1648998B1 (en) * | 2003-07-18 | 2014-10-01 | Amgen Inc. | Specific binding agents to hepatocyte growth factor |
WO2005047325A2 (en) | 2003-11-07 | 2005-05-26 | Amgen Inc. | Monkey immunoglobulin sequences |
PT1718677E (en) | 2003-12-19 | 2012-07-18 | Genentech Inc | Monovalent antibody fragments useful as therapeutics |
CN101171263A (en) * | 2005-03-04 | 2008-04-30 | 比奥根艾迪克Ma公司 | Methods of humanizing immunoglobulin variable regions through rational modification of complementarity determining residues |
WO2006116260A2 (en) | 2005-04-26 | 2006-11-02 | Medimmune, Inc. | Modulation of antibody effector function by hinge domain engineering |
CA2619244A1 (en) | 2005-08-15 | 2007-02-22 | Arana Therapeutics Limited | Engineered antibodies with new world primate framework regions |
JP5259423B2 (en) | 2006-02-01 | 2013-08-07 | セファロン・オーストラリア・ピーティーワイ・リミテッド | Domain antibody construct |
US20080139790A1 (en) | 2006-12-08 | 2008-06-12 | Jennings Philip A | Chimeric antibodies |
US20110077383A1 (en) | 2007-07-03 | 2011-03-31 | Medimmune, Llc | Hinge domain engineering |
SG190572A1 (en) | 2008-04-29 | 2013-06-28 | Abbott Lab | Dual variable domain immunoglobulins and uses thereof |
US20110123527A1 (en) | 2008-05-23 | 2011-05-26 | Hiroaki Shizuya | Method of generating single vl domain antibodies in transgenic animals |
-
2006
- 2006-12-20 US US11/659,009 patent/US7981414B2/en not_active Expired - Fee Related
- 2006-12-20 KR KR1020087017659A patent/KR20080080651A/en not_active Application Discontinuation
- 2006-12-20 AU AU2006326867A patent/AU2006326867A1/en not_active Abandoned
- 2006-12-20 EP EP06828046A patent/EP1969010A4/en not_active Withdrawn
- 2006-12-20 AU AU2006326937A patent/AU2006326937B2/en not_active Ceased
- 2006-12-20 EP EP06840403A patent/EP1969009A4/en not_active Withdrawn
- 2006-12-20 EA EA200870072A patent/EA017710B1/en not_active IP Right Cessation
- 2006-12-20 JP JP2008546030A patent/JP5179374B2/en not_active Expired - Fee Related
- 2006-12-20 US US12/158,034 patent/US20090286962A1/en not_active Abandoned
- 2006-12-20 WO PCT/AU2006/001993 patent/WO2007070979A1/en active Application Filing
- 2006-12-20 CA CA002634083A patent/CA2634083A1/en not_active Abandoned
- 2006-12-20 WO PCT/AU2006/001940 patent/WO2007070948A1/en active Application Filing
- 2006-12-20 CA CA002634080A patent/CA2634080A1/en not_active Abandoned
- 2006-12-20 JP JP2008546037A patent/JP2009519983A/en active Pending
-
2011
- 2011-01-18 US US13/008,342 patent/US8263076B2/en not_active Expired - Fee Related
-
2012
- 2012-08-14 US US13/585,192 patent/US20130040383A1/en not_active Abandoned
Patent Citations (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030199679A1 (en) * | 1990-12-21 | 2003-10-23 | Adair John Robert | Recombinant antibodies specific for TNF-alpha |
US5994510A (en) * | 1990-12-21 | 1999-11-30 | Celltech Therapeutics Limited | Recombinant antibodies specific for TNFα |
US6821505B2 (en) * | 1997-03-03 | 2004-11-23 | Board Of Regents, The University Of Texas System | Immunoglobin-like domains with increased half lives |
US20030143682A1 (en) * | 2000-11-07 | 2003-07-31 | Nicolaides Nicholas C. | Antibodies and methods for generating genetically altered antibodies with high affinity |
US20040101905A1 (en) * | 2000-12-01 | 2004-05-27 | Brekke Ole Henrik Andre | Product |
US20030118592A1 (en) * | 2001-01-17 | 2003-06-26 | Genecraft, Inc. | Binding domain-immunoglobulin fusion proteins |
US20050271663A1 (en) * | 2001-06-28 | 2005-12-08 | Domantis Limited | Compositions and methods for treating inflammatory disorders |
US20040132101A1 (en) * | 2002-09-27 | 2004-07-08 | Xencor | Optimized Fc variants and methods for their generation |
US20060034845A1 (en) * | 2002-11-08 | 2006-02-16 | Karen Silence | Single domain antibodies directed against tumor necrosis factor alpha and uses therefor |
US20060083747A1 (en) * | 2002-12-27 | 2006-04-20 | Domantis Limited | Fc fusion |
US20070269449A1 (en) * | 2003-03-26 | 2007-11-22 | Apogenix Gmbh | Fc Fusion Proteins |
US20050226863A1 (en) * | 2003-11-20 | 2005-10-13 | Massachusetts Institute Of Technology | Single-domain antibodies and uses thereof |
US20090075338A1 (en) * | 2004-03-08 | 2009-03-19 | Zymogenetics, Inc | Dimeric fusion proteins and materials and methods for producing them |
US20060038027A1 (en) * | 2004-03-15 | 2006-02-23 | Boston Scientific Scimed, Inc. | Apparatus and method for fine bore orifice spray coating of medical devices and pre-filming atomization |
US20060024308A1 (en) * | 2004-07-06 | 2006-02-02 | Roberto Crea | High affinity anti-TNF-alpha antibodies and method |
US20070111281A1 (en) * | 2005-05-09 | 2007-05-17 | Glycart Biotechnology Ag | Antigen binding molecules having modified Fc regions and altered binding to Fc receptors |
US20090226428A1 (en) * | 2005-12-20 | 2009-09-10 | Arana Therapeutic Limited | Anti-inflammatory dab |
US20080071063A1 (en) * | 2006-02-03 | 2008-03-20 | Medimmune, Inc. | Protein Formulations |
US20080227958A1 (en) * | 2006-04-14 | 2008-09-18 | Trubion Pharmaceuticals Inc. | Binding proteins comprising immunoglobulin hinge and fc regions having altered fc effector functions |
US20080260738A1 (en) * | 2007-04-18 | 2008-10-23 | Moore Margaret D | Single chain fc, methods of making and methods of treatment |
US20090148905A1 (en) * | 2007-11-30 | 2009-06-11 | Claire Ashman | Antigen-binding constructs |
US20090250012A1 (en) * | 2008-01-16 | 2009-10-08 | Jeffrey Hayden Greene | Automated systems for feeding animals and collecting animal excrement |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20080095767A1 (en) * | 2005-08-15 | 2008-04-24 | Peptech Limited | Engineered antibodies with new world primate framework regions |
US20090226428A1 (en) * | 2005-12-20 | 2009-09-10 | Arana Therapeutic Limited | Anti-inflammatory dab |
US7981414B2 (en) | 2005-12-20 | 2011-07-19 | Cephalon Australia Pty Ltd | Anti-inflammatory dAb |
US20110237780A1 (en) * | 2005-12-20 | 2011-09-29 | Peptech Limited | Anti-inflammatory dab |
US8263076B2 (en) | 2005-12-20 | 2012-09-11 | Cephalon Australia Pty Ltd. | Anti-inflammatory dAb |
US20070202105A1 (en) * | 2006-02-01 | 2007-08-30 | Peptech Limited | Domain antibody construct |
US7846439B2 (en) | 2006-02-01 | 2010-12-07 | Cephalon Australia Pty Ltd | Domain antibody construct |
US20110044979A1 (en) * | 2006-02-01 | 2011-02-24 | Doyle Anthony G | Domain antibody construct |
US20080255343A1 (en) * | 2006-12-08 | 2008-10-16 | Arana Therapeutics Limited | Chimeric antibodies |
Also Published As
Publication number | Publication date |
---|---|
CA2634083A1 (en) | 2007-06-28 |
JP5179374B2 (en) | 2013-04-10 |
KR20080080651A (en) | 2008-09-04 |
EP1969009A1 (en) | 2008-09-17 |
US20130040383A1 (en) | 2013-02-14 |
EA017710B1 (en) | 2013-02-28 |
AU2006326937B2 (en) | 2012-01-19 |
WO2007070979A1 (en) | 2007-06-28 |
AU2006326937A1 (en) | 2007-06-28 |
EP1969010A1 (en) | 2008-09-17 |
JP2009519983A (en) | 2009-05-21 |
WO2007070948A1 (en) | 2007-06-28 |
JP2009519720A (en) | 2009-05-21 |
US8263076B2 (en) | 2012-09-11 |
CA2634080A1 (en) | 2007-06-28 |
US20090226428A1 (en) | 2009-09-10 |
US20110237780A1 (en) | 2011-09-29 |
US7981414B2 (en) | 2011-07-19 |
AU2006326867A1 (en) | 2007-06-28 |
EP1969009A4 (en) | 2009-07-22 |
EA200870072A1 (en) | 2009-04-28 |
EP1969010A4 (en) | 2009-07-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20090286962A1 (en) | Chimeric antibodies with part new world primate binding regions | |
US8324350B2 (en) | Dual-specific IL-1α/IL-1β antibodies | |
KR101318549B1 (en) | Antibodies against human il17 and uses thereof | |
WO2007060411A1 (en) | Anti-tnf alpha antibodies which selectively inhibit tnf alpha signalling through the p55r | |
CN107428838B (en) | Novel antibodies that bind TFPI and compositions comprising the same | |
JP2017502924A (en) | IL-17A binding agent and use thereof | |
TW201039847A (en) | Antibodies against human tweak and uses thereof | |
TW201536806A (en) | Novel anti-human TSLP receptor antibody | |
EP1817344B1 (en) | ANTI-TNF ALPHA ANTIBODIES WHICH SELECTIVELY INHIBIT TNF ALPHA SIGNALLING THROUGH THE p55R | |
US10689452B2 (en) | Monovalent anti-huTNFR1 antibodies, encoding nucleic acids thereof and methods of treatment thereof | |
CN114144431B (en) | Humanized anti-TNF alpha antibodies and uses thereof | |
NZ569406A (en) | Chimeric antibodies with part new world primate binding regions | |
US20240059799A1 (en) | Anti-tl1a antibodies and methods of use thereof | |
JP2023507280A (en) | Multispecific antibodies with binding specificity for human IL-13 and IL-17 | |
KR102284435B1 (en) | Humanization of rabbit antibodies using a universal antibody framework | |
CA2376882A1 (en) | Novel recombinant antibody, amino acid sequences of its complementarity determining regions and genes encoding the same | |
AU2014227505A1 (en) | Engineered rabbit antibody variable domains and uses thereof | |
MX2008008029A (en) | Anti-inflammatory dab |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: ARANA THERAPEUTICS LIMITED, AUSTRALIA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:DOYLE, ANTHONY G.;JENNINGS, PHILIP A.;REEL/FRAME:022210/0341 Effective date: 20081001 |
|
AS | Assignment |
Owner name: DOMANTIS LIMITED, UNITED KINGDOM Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:TOMLINSON, IAN;WOOLVEN, BENJAMIN;REEL/FRAME:023730/0202 Effective date: 20091102 |
|
AS | Assignment |
Owner name: CEPHALON AUSTRALIA PTY LTD, AUSTRALIA Free format text: CHANGE OF NAME;ASSIGNOR:ARANA THERAPEUTICS PTY LTD;REEL/FRAME:024647/0286 Effective date: 20100210 Owner name: ARANA THERAPEUTICS PTY LTD, AUSTRALIA Free format text: CHANGE OF NAME;ASSIGNOR:ARANA THERAPEUTICS LIMITED;REEL/FRAME:024647/0289 Effective date: 20091127 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |